The Cleveland Clinic Foundation Center for Continuing Education and VEITHsymposium acknowledge educational grants in support of this activity from:
CONTENTS

Acknowledgments.................Inside Front Cover
General Information.................................7
Accreditation..............................................9
Faculty Disclosure......................................9
Social Events .............................................10
Hotel and Travel.........................................10
Agenda.....................................................11–71
Faculty Listing..........................................73–80
Registration................................................81–82
Save the Date............................Inside Back Cover
17th European Vascular Course
March 10-12, 2013
Maastricht, The Netherlands
www.vascular-course.com

1250 participants
84 invited lectures
42 company presentations
2 high quality textbooks
Vascular International Masterclass
Vascular Access Masterclass
European Venous Masterclass
Interactive Case Discussions
Hands-on courses, EVC e-Learning

Learning by training
Emerging Management Options for Pulmonary Embolism

COURSE LEADER
Michael R. Jaff, DO

Endovenous Management of Varicose Veins

COURSE LEADERS
Jose I. Almeida, MD, RVT
Lowell S. Kabnick, MD

Hemodialysis Access

COURSE LEADERS
Larry A. Sheer, MD
Thomas M. Vesely, MD

Management of Proximal Venous Obstruction

COURSE LEADERS
Kenneth Ouriel, MD, MBA
Peter Gloviczki, MD

WOUNDS

COURSE LEADER
Dieter O. Mayer, MD

POSTER SESSION

JUDGES
Peter Gloviczki, MD
Ali F. AbuRahma, MD
Ali Amin, MD, RVT
Enrico Ascher, MD
Giorgio M. Biasi, MD
Piergiorgio Cao, MD
Nicholas J.W. Cheshire, MD
Kris L. Ivancev, MD, PhD
Christos D. Liapis, MD
Frans L. Moll, MD, PhD
Kenneth Ouriel, MD, MBA
Dieter Raithel, MD, PhD
Vicente Riambau, MD, PhD
Norman M. Rich, MD
Carlo Setacci, MD
Matt M. Thompson, MD
Eric L.G. Verhoeven, MD, PhD
SPECIAL NON-CME ACCREDITED ACTIVITY  
AT VEITHsymposium

VIDEO SESSION FEATURING COMPLICATIONS AND UNUSUAL CASES

Wednesday, November 14, 2012 - 5:30 P.M. – 7:45 P.M.
Trianon Ballroom, 3rd Floor
5:30 P.M.  Cocktails and Heavy Hors d’oeuvres will be served throughout the evening.

Moderators: Plinio Rossi, MD  
Carlo Setacci, MD  
Frank J. Veith, MD

5:45 – 5:55  Endovascular Treatment Of An 8-Week-Old Embolic Occlusion Of The Popliteal Trifurcation  
Nicolas A. Diehm, MD

5:55 – 6:00  Discussion

6:00 – 6:10  Pedal Revascularization  
Thomas Rand, MD

6:10 – 6:15  Discussion

6:15 – 6:25  Evolution Of The Proximal Neck And Aneurysm Rupture Post EVAR: Endovascular Options  
Daniele Gasparini, MD

6:25 – 6:45  Discussion

6:45 – 6:55  Unusual Aortic Reinterventions  
Robert A. Morgan, MD

6:55 – 7:00  Discussion

7:00 – 7:10  How To Survive A Potential Catastrophic Complication During EVAR  
Fabrizio Fanelli, MD

7:10 – 7:15  Discussion

7:15 – 7:25  Iatrogenic Arterial Ruptures During Endovascular Procedures  
Andrej Schmidt, MD

7:25 – 7:30  Discussion

7:30 – 7:40  Unexpected Successful Access For BTA Treatment  
Marco Manzi, MD

7:40 – 7:45  Discussion

7:45  Adjourn
NEEDS ASSESSMENT

Vascular disease in all of its manifestations is a leading cause of death and disability affecting a large percentage of Americans over the age of 50. There is a critical need for physicians who diagnose, treat and manage patients with vascular disease to receive continuing medical education in this area. The latest pharmacologic, radiologic, surgical and endovascular techniques and technologies will be presented, along with discussions of when these treatments are justified and indicated and when they are not. Updates on clinical trials and opportunities for dialogue with experts in the field provide insight along with the latest data on the results of the various treatment modalities.

There is an enormous gap between actual practice and the current state of knowledge. This gap is filled imperfectly with material in books and published articles. These sources are also often negatively influenced by the biases of authors, reviewers and editors. VEITHsymposium attempts to fill this gap more perfectly and more currently by enlisting speakers with up-to-date information and data, and also those on both sides of controversial issues. In this way, the audience gets a current view of the state-of-the-art in vascular disease management as of the date of the meeting. All important topics are covered.

In addition, by having numerous short (5-6 minutes) talks followed by panel discussions and capturing the entire meeting on the web based library, the meeting will provide an electronic reference source to help vascular specialists in their practice decisions throughout the year. It will also provide the most up-to-date unbiased information possible to help with these decisions.

FOCUS

The VEITHsymposium provides Vascular Surgeons and other Vascular Specialists with a five-day conference on the most current information about new developments in clinical practice and relevant research. Beginning Wednesday, the symposium offers over 750 fast-paced presentations on what is new and important in the treatment of vascular disease. Important updates and reevaluations, as well as the latest significant advances, changing concepts in diagnosis and management, pressing controversies and new techniques, agents and diagnostic modalities will be presented. Video case presentations will also be included.

OBJECTIVES

Upon completion of the VEITHsymposium, the participants will, after learning about a wide array of topics, be able to:

- Provide information about the latest technologies, techniques and data from clinical trials for endovascular repair of AAAs and thoracic and abdominal aortic disease
- Provide information about the latest data, techniques and technologies for carotid disease management
- Provide information about the latest developments in pharmacologic agents for the management of vascular disease
- Provide information on the latest state-of-the-art for the treatment of superficial femoral and tibial artery disease
- Provide new information about the treatment of venous disease
- Provide new information about the latest developments in hemodialysis access
- Provide information about new developments in wound care
- Provide updated information about the medical or non-interventional management of vascular disease
TARGET AUDIENCE
Vascular Surgeons, Interventional Radiologists, Interventional Cardiologists, Vascular Medicine Specialists and all others interested in the management of vascular disease.

TRANSLATION LANGUAGES
We will have translation from English to Spanish, Portuguese, Russian and Mandarin Chinese from Thursday to Sunday.

SIXTH ANNUAL POSTER SESSION
This year, VEITHsymposium in collaboration with the International Society for Vascular Surgery (ISVS) will continue its feature designed to allow vascular surgeons who are ISVS members to present their work at the meeting. Posters selected by a distinguished panel of judges (Drs. Peter Gloviczki, Ali AbuRahma, Ali Amin, Enrico Ascher, Giorgio Biasi, Piergiorgio Cao, Nicholas Cheshire, Krassi Ivancev, Christos Liapis, Frans Moll, Kenneth Ouriel, Dieter Raithel, Vicente Riambau, Norman Rich, Carlo Setacci, Matt Thompson, and Eric Verhoeven) will be available for viewing throughout the meeting in the Rhinelander Gallery, 2nd floor. The formal Poster Session judging will be open to all interested attendees on Friday afternoon from 2:00 p.m. to 4:30 p.m. The distinguished panel of judges will select the 3 best poster presentations for awards on the basis of the poster and 3-minute oral presentations. These awards will be presented on Saturday, November 17, 2012 in the Grand Ballroom East, 3rd floor.

GENERAL SESSIONS
General Sessions will be held in the Grand Ballroom East and West on the 3rd floor on Thursday, Friday, Saturday and Sunday.

Wednesday Component Sessions will be held as follows:

- **Hemodialysis Access**
  - **Location:** Trianon Ballroom, 3rd floor

- **Emerging Management Options For Pulmonary Embolism**
  - **Location:** Grand Ballroom West, 3rd floor

- **Management Of Proximal Venous Obstruction**
  - **Location:** Grand Ballroom West, 3rd floor

- **Endovenous Management Of Varicose Veins**
  - **Location:** Grand Ballroom East, 3rd floor

WOUNDS
- **Location:** Gramercy Suites A&B, 2nd floor

- **Multidisciplinary Acute Stroke Management**
  - **Location:** Murray Hill Suites A&B, 2nd floor

VIDEO SESSION FEATURING COMPLICATIONS AND UNUSUAL CASES
Wednesday, November 14, 2012 - 5:30 P.M. - 7:45 P.M.
- **Location:** Trianon Ballroom, 3rd floor

There are some European interventionalists who are cutting edge leaders in new and better techniques for performing below knee endovascular treatments and carotid artery stenting. Some of these individuals will be included in this Wednesday evening program featuring challenging recorded live cases in these two important areas.

This program will be led by Dr. Plinio Rossi and will start at 5:30 P.M. and go until approximately 7:45 P.M., with ample time for audience discussion and questions. This program will provide a state-of-the-art update on exciting new treatment techniques. Cocktails and heavy hors d’oeuvres will be provided throughout the evening, courtesy of Cook Medical. (This is a non-CME activity.)
ACCREDITATION STATEMENT
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 52 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

CME CERTIFICATES AND COURSE EVALUATION FORMS
Your CME certificate will be available online at www.veithsymposium.org. An e-mail will be sent to all registered attendees immediately following the meeting with a unique password and instructions on how to obtain the certificate and complete a brief, optional course evaluation. Please note that the e-mail will be sent to the e-mail address that was used to register the attendee.

FACULTY DISCLOSURE
The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Commercial Support requiring resolution of all faculty conflicts of interest. Faculty declaring a relevant commercial interest will be identified in the activity syllabus.

ADA STATEMENT
The Cleveland Clinic Foundation Center for Continuing Education complies with the legal requirements of the Americans with Disability Act. If any participant of the VEITHsymposium requires special assistance, please send written request at least one month prior to the activity to admin@veithsymposium.org, or by fax to (845) 368-2324.

ONLINE ACCESS TO ABSTRACTS
All conference attendees will receive instructions on how to access and print out available meeting abstracts prior to the meeting. These abstracts will be available on the program page of the VEITHsymposium web site at www.veithsymposium.org. Abstracts will be available on the web site for one full year.

ONLINE CONFERENCE LIBRARY
The entire program with all the talks, all the slides, all the videos - fully synchronized - and all the panels, will be available in an Online Conference Library, which can be obtained at a nominal cost. For more information on how to obtain the VEITHsymposium Online Library, please call 800-987-9314, ext. 300.
GENERAL INFORMATION

HOTEL AND TRAVEL

A block of rooms has been reserved at the conference rate of $389 plus taxes per night. This rate is available until the block is filled or until October 19, 2012. Please request the VEITH rate when reserving your accommodations.

Hilton New York (Symposium Site)
1335 Avenue of the Americas
New York, NY 10019
(212) 586-7000 or 1-800-HILTONS (toll free U.S. only)

American Express Business Travel at The Cleveland Clinic Foundation
9500 Euclid Avenue, P83
Cleveland, OH 44195
Phone: (800) 955-6111 (U.S. toll free)
(216) 444-2564 (U.S. and International)
Fax: (216) 444-2500
E-mail: Diane.M.Geneva@aexp.com

SOCIAL EVENTS

Tickets (Theater, Opera, Symphony, Sports, Etc.)
Marilyn Rosenblatt, Charge d’Affaires
Phone: (212) 794-2773
E-mail: blattcda@aol.com

FROM HIGH ABOVE THE WORLD TO ‘HIGH’ ABOVE NEW YORK

Thursday, November 15, 2012 - 9:30 A.M. – 3:00 P.M.

New York was selected by NASA as the permanent home for the retired Space Shuttle Enterprise.

Join our tour and be among the first to see it at its new exhibit site on the USS Intrepid, as part of the Intrepid Sea, Air and Space Museum. After viewing other exhibits on this historic aircraft carrier, our van (with guide) will take us to the High Line, currently the city’s most popular visitor attraction. A lovely meandering elevated park affording unique, spectacular views of the city, this reclaimed railroad trestle called the High Line winds its way high above the Meat Packing District and beyond through one of New York’s most exciting neighborhoods, past hotels, new residential buildings, elegant boutiques, shops, markets and restaurants in the streets below.

Then, we’ll stop for a memorable lunch at the nearby Tribeca Grill, a true New York City landmark, co-owned by renowned restaurateur Drew Nieporent and legendary actor Robert De Niro.

Cost: $125.00 (includes admission, transportation, tour guide and lunch).

To reserve space please make your check (U.S. bank only) payable to Charge d’Affaires, Inc. and mail it to Marilyn Rosenblatt, Charge d’Affaires, Inc., 75 East End Avenue, #11L, New York, NY 10028. We regret that we cannot accept payment by credit card.

For more information please call (212) 794-2773 or e-mail blattcda@aol.com.
WEDNESDAY, NOVEMBER 14, 2012

6:30 A.M. General Registration — 2nd Floor Promenade
Faculty Registration — Morgan Suite, 2nd Floor
Continental Breakfast — Sutton Complex, 2nd Floor

CONCURRENT WEDNESDAY PROGRAMS

SESSIONS 1 & 2
Hemodialysis Access
7:55 A.M. – 5:00 P.M.
Trianon Ballroom, 3rd Floor

SESSION 3
Emerging Management Options For Pulmonary Embolism
10:00 A.M. – 12:00 P.M.
Grand Ballroom West, 3rd Floor

SESSION 4
Management Of Proximal Venous Obstruction
1:00 P.M. – 3:15 P.M.
Grand Ballroom West, 3rd Floor

SESSIONS 5 & 6
Endovenous Management Of Varicose Veins
8:00 A.M. – 5:15 P.M.
Grand Ballroom East, 3rd Floor

SESSIONS 7 & 8
WOUNDS
9:00 A.M. – 5:20 P.M.
Gramercy Suites A&B, 2nd Floor

SESSIONS 9 & 10
Multidisciplinary Acute Stroke Management
7:55 A.M. – 4:00 P.M.
Murray Hill Suites A&B, 2nd Floor

SESSION 1 (Trianon Ballroom, 3rd Floor)
HEMODIALYSIS ACCESS – PART 1
7:55 – 8:00
Welcome And Introduction
Larry A. Scher, MD
Thomas M. Vesely, MD

PART 1A: INTERVENTIONAL PROCEDURES FOR HEMODIALYSIS ACCESS
Moderators: Larry A. Scher, MD
Thomas M. Vesely, MD

8:00 – 8:08
Where Is The SVC/RA Junction And Why Is It Important In The Dialysis Patient
Jacob Cynamon, MD

8:09 – 8:17
Access Survival After Prophylactic Angioplasty
Timothy A. Pfladerer, MD

8:18 – 8:26
Stent Grafts For Venous Anastomotic Stenosis
Thomas M. Vesely, MD

8:27 – 8:35
Angioplasty, Stents Or Stent Grafts For Swing-Point Or Cephalic Arch Stenosis
Theodore F. Saad, MD
PART 1B: HEMODIALYSIS CATHETERS AND NEW TECHNOLOGY

Moderators: Haimanot (Monnie) Wasse, MD, MPH
Theodore F. Saad, MD

10:15 – 10:23 Uncommon Complications Of Hemodialysis Catheters
Kenneth D. Abreo, MD

10:24 – 10:32 Inadvertent Arterial Catheterization During Central Venous Catheter Insertion
Tony P. Smith, MD

10:33 – 10:41 Translumbar Hemodialysis Catheters
Gregory J. Nadolski, MD

10:42 – 10:50 Balloon-Assisted Technique For The Placement Of The Outflow Segment Of The HeRO Device
Hector Ferral, MD

Stephen Settle, MD

11:00 – 11:08 Computational Fluid Dynamics Of Hemodialysis Grafts
Christof Karmonik, PhD

11:09 – 11:17 Vessel-Select Access System For Percutaneous AV Fistula Creation
Jeffrey E. Hull, MD

11:18 – 11:26 Arteriovenous Fistula Creation Using The Optiflow Anastomotic Connector
Prabir Roy-Chaudhury, MD, PhD

11:27 – 11:35 Blood Flow As Predictor Of Patency For Hemodialysis Access Procedures
Lars Lonn, MD, PhD

11:36 – 11:55 Panel Discussion

11:55 – 12:45 Lunch Break – Americas Hall 1, 3rd Floor
Visit Exhibits and Pavilions (2nd and 3rd Floors)
SESSION 2  (Trianon Ballroom, 3rd Floor)
HEMODIALYSIS ACCESS – PART 2

PART 2A: CLINICAL PRACTICE ISSUES I
Moderators: Thomas M. Vesely, MD
Joseph N. Shams, MD

12:45 – 12:53
Genetic Causation Of Hemodialysis Access Stenosis
Timmy Lee, MD, MSPH

12:54 – 1:02
Mathematical Model Of Brachiocephalic Fistula: New Explanation For Success Of DRIL Procedure In Treating Hand Ischemia
William D. Paulson, MD

1:03 – 1:11
The Effect Of Access Blood Flow On Cardiac Function
Louise Moist, MD, MSc

1:12 – 1:20
Targeting Catheter Last In Fistula First
Joseph A. Vassalotti, MD

1:21 – 1:36
Reducing Hemodialysis Catheters: When Is A Graft Preferred To Fistula?
Charmaine Lok, MD

1:37 – 1:45
When Should Peritoneal Dialysis Be Considered?
Jack Work, MD

1:46 – 1:59
Panel Discussion

PART 2B: CLINICAL PRACTICE ISSUES II
Moderators: Mitchell L. Henry, MD
Eric K. Peden, MD

2:00 – 2:08
Bundling And Revaluing Hemodialysis Access Services
Sean P. Roddy, MD

2:09 – 2:17
Accountable Access Care Organization
Timothy A. Pflederer, MD

2:18 – 2:26
Fistula Maturation Is Related To Logistics, Communication, Training And Competency
Prabir Roy-Chaudhury, MD, PhD

2:27 – 2:35
Training Surgeons To Perform Vascular Access
Mitchell L. Henry, MD

2:36 – 2:44
Nursing Assessment And Management Of Access Related Aneurysms And Pseudoaneurysms
Brian LaMendola, RN, MBA

2:45 – 2:53
Surgical Management Of Access Related Aneurysms And Pseudoaneurysms
Gary A. Gelbfish, MD

2:54 – 3:02
Risk Of Infection After Stent Graft Placement In Hemodialysis Grafts
Tony P. Smith, MD

3:03 – 3:25
Panel Discussion

3:25 – 3:45
Break - Visit Exhibits and Pavilions (2nd and 3rd Floors)

PART 2C: SURGICAL ISSUES IN HEMODIALYSIS ACCESS
Moderators: Marc H. Glickman, MD
A. Frederick Schild, MD

3:45 – 3:53
Can Early Cannulation Grafts Reduce Catheter Dependency?
Marc H. Glickman, MD

3:54 – 4:02
Management Of Lower Extremity Steal Syndrome
Eric K. Peden, MD

4:03 – 4:11
Endovascular And Surgical Options For Inflow Stenosis In Patients With Dysfunctional AV Access
Karl A. Illig, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:12</td>
<td>Options For Vascular Access In The Obese Patient</td>
</tr>
<tr>
<td></td>
<td>David L. Cull, MD</td>
</tr>
<tr>
<td>4:21</td>
<td>Use Of A Bovine Carotid Artery For Hemodialysis Access</td>
</tr>
<tr>
<td></td>
<td>Eric K. Peden, MD</td>
</tr>
<tr>
<td>4:30</td>
<td>Forearm Basilic Vein Transposition</td>
</tr>
<tr>
<td></td>
<td>Larry A. Scher, MD</td>
</tr>
<tr>
<td>4:39</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>5:00</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>

**SESSION 3** (Grand Ballroom West, 3rd Floor)

**EMERGING MANAGEMENT OPTIONS FOR PULMONARY EMBOLISM**

**Moderator:** Michael R. Jaff, DO

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Introduction To The Session</td>
</tr>
<tr>
<td></td>
<td>Frank J. Veith, MD</td>
</tr>
<tr>
<td>10:03</td>
<td>Welcome And Introduction Of The Topic</td>
</tr>
<tr>
<td></td>
<td>Michael R. Jaff, DO</td>
</tr>
<tr>
<td>10:09</td>
<td>What Must The Vascular Specialist Know About PE</td>
</tr>
<tr>
<td></td>
<td>Victor F. Tapson, MD</td>
</tr>
<tr>
<td>10:19</td>
<td>Intravenous rtPA For Pulmonary Embolism: Does This Work</td>
</tr>
<tr>
<td></td>
<td>Ido Weinberg, MD, MSc</td>
</tr>
<tr>
<td>10:29</td>
<td>Percutaneous Pharmacomechanical Intervention For PE: An Overview</td>
</tr>
<tr>
<td></td>
<td>Nils Kucher, MD</td>
</tr>
<tr>
<td>10:39</td>
<td>The EKOS Strategy</td>
</tr>
<tr>
<td></td>
<td>Tod C. Engelhardt, MD</td>
</tr>
<tr>
<td>10:49</td>
<td>The VORTEX Strategy</td>
</tr>
<tr>
<td></td>
<td>Christopher J. Kwolek, MD</td>
</tr>
<tr>
<td>10:59</td>
<td>Angiojet Device To Treat Massive And Submassive PEs</td>
</tr>
<tr>
<td></td>
<td>Jeffrey Y. Wang, MD</td>
</tr>
<tr>
<td>11:09</td>
<td>ECMO As The Bridge To Definitive Therapy For PE: Hybrid Approaches</td>
</tr>
<tr>
<td></td>
<td>Kenneth Rosenfield, MD</td>
</tr>
<tr>
<td>11:19</td>
<td>Less May Be More: The Use Of Catheter Directed Thrombolysis In Conjunction With IVC Filters For Mass. And Submassive PE</td>
</tr>
<tr>
<td></td>
<td>Gary M. Ansell, MD</td>
</tr>
<tr>
<td>11:29</td>
<td>Techniques, Tips And Tricks For Endovascular Management Of Pulmonary Embolism</td>
</tr>
<tr>
<td></td>
<td>Ali Amin, MD, RVT</td>
</tr>
<tr>
<td>11:39</td>
<td>Interventional Management Of Occlusive Iliofemoral Deep Venous Thrombosis: Another Evolution To A Revolution?</td>
</tr>
<tr>
<td></td>
<td>Mark H. Meissner, MD</td>
</tr>
<tr>
<td>11:49</td>
<td>Panel Discussion/Questions And Answers</td>
</tr>
<tr>
<td>12:00</td>
<td>Adjourn</td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch Break – Americas Hall 1, 3rd Floor</td>
</tr>
<tr>
<td></td>
<td>Visit Exhibits and Pavilions (2nd and 3rd Floors)</td>
</tr>
</tbody>
</table>

**SESSION 4** (Grand Ballroom West, 3rd Floor)

**MANAGEMENT OF PROXIMAL VENOUS OBSTRUCTION**

**Moderators:** Kenneth Ouriel, MD, MBA

Peter Gloviczki, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>Introduction To The Session</td>
</tr>
<tr>
<td></td>
<td>Kenneth Ouriel, MD, MBA</td>
</tr>
<tr>
<td></td>
<td>Frank J. Veith, MD</td>
</tr>
</tbody>
</table>
DEBATE: Should Acute Isolated Femoropopliteal DVT Be Managed Aggressively

1:06 – 1:13
Yes, Remove The Thrombus With Pharmacomechanical Means
Cynthia K. Shortell, MD

1:14 – 1:21
No, Anticoagulation Alone Is Best
Thomas W. Wakefield, MD

1:22 – 1:30
discussion and Vote

DEBATE: Venous Thoracic Outlet Syndrome: Intervention Or Observation?

1:31 – 1:38
Axillo-Subclavian Vein Thrombosis Should Be Treated With Early Thrombolysis, First Rib Resection And Open Venous Reconstruction
Robert W. Thompson, MD

1:39 – 1:46
There Is No Evidence That Intervention Is Better Than Anticoagulation For Acute Axillo-Subclavian Vein Thrombosis
Mark H. Meissner, MD

1:47 – 1:55
discussion and Vote

DEBATE: How Should We Manage May-Thurner Syndrome?

1:56 – 2:03
May-Thurner Syndrome Should Be Treated Aggressively With Venous Stenting In All Symptomatic Patients
Seshadri Raju, MD

2:04 – 2:11
Compression Treatment Alone Is Best For May-Thurner Syndrome
Gregory L. Moneta, MD

2:12 – 2:20
discussion and Vote

DEBATE: The Best First-Line Modality For Iliofemoral Venous Thrombus Is . . .

2:21 – 2:28
Open Surgical Thrombectomy Is The Standard
Anthony J. Comerota, MD

2:29 – 2:36
Thrombolysis With Ultrasound Is Best
Mark J. Garcia, MD

2:37 – 2:45
discussion and Vote

DEBATE: The Nutcracker Syndrome: We Can Treat It But Should We?

2:46 – 2:53
Nutcracker Syndrome Is Best Managed By Open Surgical Reconstruction
Peter Gloviczki, MD

2:54 – 3:01
Non-Aggressive Management Of Renal And Pelvic Venous Congestion Is Best
Cees H.A. Wittens, MD, PhD

3:02 – 3:10
discussion and Vote

3:11 – 3:15
Summary And Conclusions
Peter Gloviczki, MD
Kenneth Ouriel, MD, MBA

3:15
adjourn

Visit Exhibits and Pavilions (2nd and 3rd Floors)
SESSION 5  (Grand Ballroom East, 3rd Floor)
ENDOVENOUS MANAGEMENT OF VARICOSE VEINS – PART I
Moderators: Jose I. Almeida, MD, RVT
Lowell S. Kabnick, MD

8:00 – 8:06 Welcome – Endovascular Venous Surgery At A Glance
Jose I. Almeida, MD, RVT

8:07 – 8:12 Anatomy And Nomenclature Of The Venous System
Mark A. Adelman, MD

8:13 – 8:18 Standards For Venous Mapping And Reflux Study
Nicos Labropoulos, BSc (Med), PhD, DIC, RVT

8:19 – 8:24 Clinical Evaluation Of The Venous Patient
Mark H. Meissner, MD

8:25 – 8:30 Why Treat Varicose Veins: Is There Evidence?
Apostolos K. Tassiopoulos, MD

8:31 – 8:36 How To Use CEAP And VCSS In Clinical Practice?
Michael A. Vasquez, MD, RVT

8:37 – 8:42 Step-By-Step Endovenous Thermal Ablation Of The GSV
Edward G. Mackay, MD

8:43 – 8:48 Step-By-Step Endovenous Thermal Ablation Of The SSV
Caron B. Rockman, MD

8:49 – 8:54 Step-By-Step Endovenous Chemical Ablation Of The GSV
Ted King, MD

8:55 – 9:00 It Does Not Matter Which Device For Truncal Vein Ablation, The Results Are The Same
Alun H. Davies, MA, DM

9:01 – 9:06 Modern Day Stripping Is As Good As Endovenous Thermal Ablation
Cees H.A. Wittens, MD, PhD

9:07 – 9:12 Review Of Randomized Controlled Trials Comparing Endovenous Thermal And Chemical Ablation
Bo G. Eklof, MD, PhD

9:13 – 9:18 Step-By-Step: Ambulatory Phlebectomy
Paul Pittaluga, MD

9:19 – 9:24 “Powered” Phlebectomy: Are We There Yet For Significant Branch Varicosities?
Thomas W. Wakefield, MD

9:25 – 9:30 Should Adjuvant Procedures Be Performed At The Same Time As Endovenous Thermal Ablation? Evidenced Based
Peter J. Pappas, MD

9:31 – 9:36 Guidelines (USA vs UK) In The Management Of Superficial Venous Disease
Peter Gloviczki, MD

9:37 – 9:42 Endovenous Thermal Ablation: Technical Pearls For Complex Anatomy
Jose I. Almeida, MD, RVT

Lowell S. Kabnick, MD

9:49 – 9:54 When Is Prophylaxis Needed During GSV/SSV Ablation?
Caron B. Rockman, MD

9:55 – 10:00 DEBATE: C2 Venous Disease Is Progressive: Its Treatment Should Be A Covered Insurance Benefit
Alun H. Davies, MA, DM
SESSION 6  (Grand Ballroom East, 3rd Floor)

ENDOVENOUS MANAGEMENT OF VARICOSE VEINS – PART 2

Moderators: Jose I. Almeida, MD, RVT
Lowell S. Kabnick, MD

1:00 – 1:05  Compression Therapy For Lymphatic Disease Treatment: Is That All There Is?
Raghu Kolliari, MD

1:06 – 1:11  Compression: Should We Use Post Saphenous Ablation? Evidence?
Todd Berland, MD

1:12 – 1:17  Compression: Medical Necessity Requirement Prior To Treatment: Really? Evidence?
Glenn Jacobowitz, MD

1:18 – 1:23  Compression: Should We Use During Sports: Evidence?
Steve Elias, MD

1:24 – 1:29  Introduction Of IACVC: Accreditation Of Vein Centers
John Blebea, MD, MBA

1:30 – 1:35  If I Were To Build & Credential The “Ideal Vein Doctor” I Would Add These Ingredients…
Michael C. Dalsing, MD

1:36 – 1:41  Misperceptions Of The American Board of Phlebology
Anthony J. Comerota, MD

1:42 – 1:47  Update: Cyanoacrylate For GSV Ablation
Jose I. Almeida, MD, RVT

1:48 – 1:53  Update: Mechanochemical GSV Ablation
Steve Elias, MD

1:54 – 1:59  Should Endovenous Ablation Of Small Diameter Great Saphenous Veins Be Performed On Patients With Symptomatic Varicose Veins?
Alan M. Dietzek, MD, RPVI

2:00 – 2:05  Update: Steam Ablation For GSV Ablation
Renate R. van den Bos, MD, PhD

2:06 – 2:11  Can Venous Ablation Be Performed In Patients With A History Of Ipsilateral DVT?
Lowell S. Kabnick, MD

2:12 – 2:17  Where Will We Be In 2015?
Lowell S. Kabnick, MD

2:18 – 2:23  Present And Future Of Chronic Cerebrospinal Venous Insufficiency (CCVSI): Is This A Real Syndrome?
Mark H. Meissner, MD

2:24 – 2:29  CCSVI: Our Results And Should We Continue To Treat?
Marzia Lugli, MD

2:30 – 2:35  The Next Breakthrough In Venous Research
Joseph D. Raffetto, MD

2:36 – 2:41  Is Venous Disease Arterial?
Seshadri Raju, MD

2:42 – 2:47  Implications Of Expanded Venous Reflux Study
Thomas W. Wakefield, MD

2:48 – 2:53  Detecting Iliac, IVC, Ovarian Vessels By Duplex Ultrasound
Judy M. Holdstock, DMU, DCR

2:54 – 2:59  Pelvic Reflux With Or Without Pelvic Symptoms (C2 Or Higher): Should We Treat And How?
Mark S. Whiteley, MS

3:00 – 3:05  Best Imaging Techniques For Deep Venous Evaluation
Barry Stein, MD

Robert B. McLafferty, MD
Proposed Classification System For Iliocaval Occlusion
William A. Marston, MD

Iliac Vein Stenting For Advanced Chronic Venous Disease: When Will It Improve Symptoms And When Will It Not?
Enrico Ascher, MD

My Approach To Iliac Vein Outflow Occlusive Disease
Jose I. Almeida, MD, RVT

Endovascular Treatment Of Chronic Venous Obstruction: Tips And Tricks Including Complete Obstruction
Mark J. Garcia, MD

DEBATE: We Should Treat Intramuscular Calf Vein DVT With Standard Anticoagulation
Joann Lohr, MD

DEBATE: We Should Not Treat Intramuscular Calf Vein DVT With Standard Anticoagulation
Clifford M. Sales, MD, MBA

Superficial Venous Thrombophlebitis: To Treat Or Not To Treat?
Joseph D. Raffetto, MD

2012 Chest Guidelines - Important Changes
Anthony J. Comerota, MD

Importance Of A Venous Registry And Opportunities In The Vascular Quality Initiative (SVS)
Jack L. Cronenwett, MD

What Drugs Should We Be Using For DVT Treatment?
Russell H. Samson, MD, RVT

Timing And Patient Selection For Thrombolysis
Antonios P. Gasparis, MD

Should We Use The D-Dimer Test And/Or Residual Thrombus To Manage DVT?
Timothy K. Liem, MD

Association Of Deep Vein Reflux And Obstruction In PTS: Which Is The Culprit?
Seshadri Raju, MD

What Is A Saphenous Vein Aneurysm And How Should It Be Treated
Ronald G. Bush, MD

Mechanism Of Venous Valve Closure And The Role Of The Valve In Circulation
Fedor Lurie, MD, PhD

Deep Venous Valvular Reconstruction: Indications, How And Results
Marzia Lugli, MD

Natural History Of Advanced CVI (CEAP 4-6) Following Endovenous Ablation
Jennifer A. Heller, MD

Panel Discussion
Panelists: Jose I. Almeida, MD, RVT
Enrico Ascher, MD
Lowell S. Kabnick, MD
Anthony J. Comerota, MD
Jack L. Cronenwett, MD
Alan M. Dietzek, MD, RPVI
Antonios P. Gasparis, MD
Marzia Lugli, MD
William A. Marston, MD
Mark H. Meissner, MD
Mark S. Whiteley, MD

Adjourn
SESSION 7 (Gramercy Suites A&B, 2nd Floor)
WOUNDS – PART 1

9:00 – 9:10 Opening Remarks
Dieter O. Mayer, MD

PART 1A: NEW CONCEPTS IN WOUND CARE
Moderator: Giacomo Clerici, MD

9:10 – 9:20 Utility Of V.A.C.® Therapy For Split-Thickness Skin Grafting
Bauere Sumpio, MD, PhD

9:20 – 9:30 Discussion

9:30 – 9:40 Topical Oxygen; Breathing New Life Into Chronic Wounds
Giacomo Clerici, MD

9:40 – 9:50 Discussion

9:50 – 10:00 Diagnosis And Management Of Atypical Wounds Of The Lower Leg: An Update
Marco Romanelli, MD, PhD

10:00 – 10:10 Discussion

10:10 – 10:20 A Systematic Approach To Surgical Debridement
Dieter O. Mayer, MD

10:20 – 10:30 Discussion

10:30 – 11:00 Break – Visit Exhibits and Pavilions (2nd and 3rd Floors)

PART 1B: FREE PAPER SESSION
Moderator: Dieter O. Mayer, MD

11:00 – 11:07 Critical Limb Ischemia: Endovascular Below-The-Knee Maximal Revascularization Increases Wound Healing
Nirvana Sadaghianlou, MD

11:07 – 11:12 Discussion

11:12 – 11:19 Maggot Therapy For Chronic Ulcer: Systematic Review, Meta-analysis And Cost-Effective
Chumphon Wilasrusmee, MD, MSc

11:19 – 11:24 Discussion

11:24 – 11:31 A Novel Robotic Monofilament Test For Diabetic Neuropathy
Chumphon Wilasrusmee, MD, MSc

11:31 – 11:36 Discussion

11:36 – 11:43 Can Audible Doppler Signal Be Used As An Alternative To Ankle Brachial Pressure Index
Afsaneh Alavi, MD

11:43 – 11:48 Discussion

11:48 – 11:55 How Frequently Does A Malignant Wound Present As Leg Ulcer?
Afsaneh Alavi, MD

11:55 – 12:00 Discussion

12:00 – 12:30 Lunch Break – Americas Hall 1, 3rd Floor
Visit Exhibits and Pavilions (2nd and 3rd Floors)

SESSION 8 (Gramercy Suites A&B, 2nd Floor)
WOUNDS – PART 2

PART 2A: EVIDENCE BASED MEDICINE IN WOUND CARE
Moderator: Bauere Sumpio, MD, PhD

12:30 – 12:40 How To Implement EBM In Our Wound Clinic Or Surgical Department
Hester Vermeulen, PhD
12:40 – 12:50
Delphi Studies In Wound Care Research: A New Better Tool For EBM?
Anne M. Eskes, RN, MSc

12:50 – 1:00
How To Treat Donor Site Wounds: An Evidence Based Approach
Fleur E. Brölmann, MD

1:00 – 1:20
Panel Discussion

1:20 – 1:30
The Association Of Ulceration Of The Foot With Cardiovascular And All-Cause Mortality In Patients With Diabetes: A Meta-analysis
Robert J. Hinchliffe, MD

1:30 – 1:40
Evidence Based Update: Diabetic Foot Ulcers And The Wound Bed Preparation Model
R. Gary Sibbald, MD

1:40 – 1:50
Panel Discussion

PART 2B: CONCEPTS FOR THE DIABETIC FOOT
Moderators: Giacomo Clerici, MD
Marc A. Brenner, DPM

1:50 – 2:10
Facts That Every Vascular Surgeon Needs To Know About The Diabetic Foot
Michael E. Edmonds, MD

2:10 – 2:20
Discussion

2:20 – 2:40
Foot Deformities In The Diabetic - More Than Charcot Foot
Thomas Boeni, MD

2:40 – 2:50
Discussion

2:50 – 3:00
A New Device For Topical Intermittent Rapid Oxygenation – Compression To Increase Hyperoxygenated Blood Flow To The Horrendous Septic Diabetic Foot
Magdiel Trinidad-Vasquez, MD

3:00 – 3:10
Discussion

3:10 – 3:20
Achilles Tendon Complete Tenotomy: THE Solution For Treating Neuropathic Diabetes Mellitus Foot Ulcers?
Wayne Caputo, DPM

3:20 – 3:30
Discussion

3:30 – 3:50
Break – Visit Exhibits and Pavilions (2nd and 3rd Floors)

PART 2C: VASCULAR INTERVENTIONS IN WOUND CARE
Moderator: Joseph L. Mills, MD

3:50 – 4:00
Peripheral VORTEC Procedures: Who Really Profits And Who Maybe Does Not?
Gabriel Szendro, MD

4:00 – 4:10
Discussion

4:10 – 4:20
Provide Me An Inflow And I Will Heal Your Foot
Marc A. Brenner, DPM

4:20 – 4:30
Discussion

4:30 – 4:40
Below-The-Knee Stent Or Balloon In Severe Critical Limb Ischemia With Extensive Wounds: Is It Worth The Effort?
Sebastian E. Debus, MD, PhD

4:40 – 4:50
Discussion

4:50 – 5:00
Is Tibial Angioplasty Effective To Improve Wound Healing In Patients With End-Stage Renal Disease (ESRD)?
Werner Lang, MD

5:00 – 5:10
Discussion
SESSION 9  (Murray Hill Suites A&B, 2nd Floor)
MULTIDISCIPLINARY ACUTE STROKE MANAGEMENT – PART I

7:55 – 8:00 Welcome And Introduction
Allan L. Brook, MD

PART 1A: THE BASICS OF STROKE - INCLUDING THE EPIDEMIOLOGY AND NATURAL HISTORY

Moderators: Allan L. Brook, MD
Joshua A. Hirsch, MD

8:00 – 8:07 Stroke: Where We Have Been And Now The 21st Century And Things To Look Forward To
Lou Caplan, MD

8:08 – 8:16 TIAs - What Is New: Diagnosis And When To Treat Aggressively
David S. Liebeskind, MD

Colin P. Derdeyn, MD

8:26 – 8:34 Posterior Fossa: Why Do We Have A Longer Window? Or Do We Just Not Understand The Physiology?
Lou Caplan, MD

8:35 – 8:47 The Clinical Exam: Quick Pearls That Tell You: Large Or Small Vessel Occlusion
Daniel L. Labovitz, MD

8:48 – 8:56 Door To Revascularization Time: Optimization And Where Should We Be In 5 Years And Why
Edward C. Jauch, MD, MS

8:57 – 9:16 Panel Discussion

PART 1B: STATE-OF-THE-ART IMAGING

Moderators: Lawrence Wechsler, MD
David S. Liebeskind, MD

9:17 – 9:25 Why Does Clot Location, Composition And Size Really Matter?
Albert J. Yoo, MD

9:26 – 9:34 The Neuroimaging Protocol Made Easy: Quick, Accurate And Reliable Anatomic And Physiologic Imaging
Howard A. Rowley, MD

9:35 – 9:47 Summarization Of The Latest Trials And Learning Points
Lawrence Wechsler, MD

9:48 – 9:56 Collaterals And Definitive Reperfusion
David S. Liebeskind, MD

9:57 – 10:15 Panel Discussion

10:15 – 10:30 Break – Visit Exhibits and Pavilions (2nd and 3rd Floors)

PART 1C: TRIAGE ISSUES AND DEBATES

Moderators: Edward C. Jauch, MD, MS
Lawrence Wechsler, MD

10:31 – 10:38 Triage At Its Best: My Brooklyn Pearls
Steven H. Rudolph, MD
10:39 – 10:46
"Telestroke" 2012: From Far And Away The Specialist Can Make The Difference
Leonard Dimitri DaSilva, MD

10:47 – 10:53
Why Has Imaging Failed To Find The Optimum Patients For Revascularization?
Lawrence Wechsler, MD

10:54 – 11:00
Best Stroke Imaging Of The Future And Why
Pamela W. Schaefer, MD

PART 1D: ACUTE STROKE TREATMENT
Moderators: Peter A. Rasmussen, MD
Joshua A. Hirsch, MD

11:01 – 11:08
IV TPA Recent Updated Guidelines: Does 3, 4, Or 6 Hours Really Have A Basis In The Literature Or In Pathophysiology?
Osama O. Zaidat, MD

11:08 – 11:16
IA Medical Nuances - When And How Much: Does Temporary Stenting Revisit The Need For Thrombolytics
Don Fré, MD

11:17 – 11:23
Thrombectomy: Summary Of The Clotted Data And Outcomes
Aquilla S. Turk, DO

11:24 – 11:31
Antiplatelet Therapy And Beyond: How It Relates To Intracranial Stenting And More
Lucie G. Thibault, Pharm.D

11:32 – 11:39
Angioplasty, Stenting And Temporary Stenting (A True Bridging Protocol): Facts And Fictions: My Opinion!
David Fiorella, MD

11:40 – 11:47
Is It Device Or Patient Criteria That Are Most Important To Make An Impact In Early Revascularization With Efficacy?
Peter A. Rasmussen, MD

11:48 – 12:00
Panel Discussion

SESSION 10 (Murray Hill Suites A&B, 2nd Floor)
MULTIDISCIPLINARY ACUTE STROKE MANAGEMENT – PART 2

PART 2A: POWER LUNCHEON SYMPOSIUM: CAROTID AND INTRACRANIAL STENTING: WHAT WENT WRONG WITH THE TRIALS?
Moderators: Thomas G. Brott, MD
Joshua A. Hirsch, MD
Peter K. Nelson, MD
Philip M. Meyers, MD

12:15 – 12:25
CREST: Salient Points And Implications For The Future
Thomas G. Brott, MD

12:26 – 12:36
Facts, Unknowns And Reasons For The Ongoing Controversy About The Best Treatment For Asymptomatic Carotid Stenosis
Frank J. Veith, MD

12:37 – 12:47
Doppler Is Not Enough To Send My Patient For Revascularization And Why: The Neurological Perspective
Don Heck, MD

12:48 – 12:59
Discussion
PART 1:

1:00 – 1:10
SAMMPRIS: Summary From The PI And Future Implications
Colin P. Derdeyn, MD

1:11 – 1:21
SAMMPRIS Results: Why I Advocate A New Trial And Why Patients Need Technology
David Fiorella, MD

1:22 – 1:32
IMS III – Latest Trial Results And Reason To Pause, Or Proceed With New Interest And Ideas: Unofficial Comments
Edward C. Jauch, MD, MS

1:33 – 1:43
Stroke Trials: Lessons Learned: The Next Horizon To Make An Impact On Stroke Reversal Or Prevention
J. Mocco, MD, MS

1:44 – 1:59
Discussion

PART 2B:

THE OTHER SIDE OF STROKE: SUBARACHNOID HEMORRHAGE MANAGEMENT

Moderators: David Gordon, MD Aquilla S. Turk, DO

2:00 – 2:10
Subarachnoid Hemorrhage: Vasospasm Latest Developments
Aman B. Patel, MD

2:11 – 2:21
Neuroanesthesia: Elements For Success
Apalonia E. Abramowicz, MD

2:22 – 2:32
Latest Devices For Aneurysm Therapy: Are Coils Becoming The Second Option?
Peter K. Nelson, MD

2:33 – 2:43
Surgical Clipping Of Aneurysms Is Still A Necessary Evil: Case Selection From An Experienced Cerebrovascular Neurosurgeon
Eugene S. Flamm, MD

2:44 – 2:54
Endovascular Cases That Make Me Nervous: Location, Geometry, And Beyond
Aaron S. Dumont, MD

2:55 – 3:05
Unruptured Aneurysms: Why Do We Treat Them? The US Experience vs. The Rest Of The World Opinion
TBD

3:06 – 3:16
Intracranial Bypass: Has A Dinosaur Come Back From Extinction? Best Indications And State-Of-The Art Techniques/NOVA
David J. Langer, MD

3:17 – 3:22
Most Common Medical Legal Issues
Gregg H. Zoarski, MD

3:23 – 3:28
Ways To Avoid Facing The Wrong Side Of The Jury
Michael I. Weintraub, MD

3:29 – 4:00
Discussion

4:00
Adjourn

Visit Exhibits and Pavilions (2nd and 3rd Floors)
CONCURRENT THURSDAY MORNING PROGRAMS

PROGRAM A (SESSIONS 11 – 13)
Cardiac And Thoracic Aortic Diseases And Their Treatment
6:30 A.M. – 9:54 A.M.
Grand Ballroom East and West, 3rd Floor

PROGRAM B (SESSIONS 14 – 16)
New Endovascular Approaches To Lower Extremity And Below-Knee Arterial Disease And Its Treatment
6:35 A.M. – 9:54 A.M.
Trianon Ballroom, 3rd Floor

PROGRAM A (SESSIONS 11 – 13)
TOPICS DEALING WITH CARDIAC AND THORACIC AORTIC DISEASES AND THEIR TREATMENT
(GRAND BALLROOM EAST AND WEST, 3RD FLOOR)
6:30 – 6:35 Opening Remarks
Frank J. Veith, MD

SESSION 11 (Grand Ballroom East and West, 3rd Floor)
PROGRESS IN TRANSCATHETER HEART VALVES, NEW APPROACHES TO THE ASCENDING AORTA AND THORACIC AORTIC DISEASE
(5-MINUTE TALKS)
Moderators: Roy K. Greenberg, MD
Peter R. Taylor, MA, MChir

6:35 – 6:40 Transcatheter Aortic Valve Implantation (TAVI) For Unsatisfactory Surgical Valve Implantations: Will It Be An Exception Or The Routine In The Future
Dietmar H. Koschyk, MD

6:41 – 6:46 Why Vascular Surgeons Must Play A Role In TAVI Procedures: Why Is Their Expertise Important
Marc R.H.M. van Sambeek, MD, PhD

6:47 – 6:52 New Developments In Transcutaneous Mitral Valve Repair
Ted Feldman, MD

6:53 – 6:58 Present Status And Future Potential Of TAVI
Martin B. Leon, MD

6:59 – 7:04 Wrapping Procedure For Dilated Ascending Aorta: When And How To Do It
Mario Lachat, MD

7:05 – 7:10 Status Of Endovascular Graft Repair For Aortic Arch Lesions: What Endovascular Solutions Are Working And What Are Not Working
Timothy A.M. Chuter, DM

7:11 – 7:16 Quantifying Ascending Aorta And Arch Deformation From Respiratory And Cardiac Motion: Implications For Branched Devices
Ronald L. Dalman, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:17 -</td>
<td>Retrograde Dissection During Endovascular Treatment Of Aortic Arch Pathology:</td>
<td>Ger mano Melissano, MD</td>
</tr>
<tr>
<td>7:22</td>
<td>How Can It Be Prevented And Treated</td>
<td>Roberto Chiesa, MD</td>
</tr>
<tr>
<td>7:23 -</td>
<td>Risk Factors Of Stroke In Thoracic Endovascular Aortic Repair (TEVAR) And</td>
<td>Wei Guo Fu, MD</td>
</tr>
<tr>
<td>7:28</td>
<td>How To Offset Them</td>
<td></td>
</tr>
<tr>
<td>7:29 -</td>
<td>Hybrid Rescue Techniques For Failed TEVAR Procedures</td>
<td>Eric E. Roselli, MD</td>
</tr>
<tr>
<td>7:34</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>7:41</td>
<td>SESSION 12 (Grand Ballroom East and West, 3rd Floor)</td>
<td></td>
</tr>
<tr>
<td>7:41 -</td>
<td>NEW DEVELOPMENTS IN TREATMENT OF THE ASCENDING AORTA, ARCH LESIONS AND</td>
<td></td>
</tr>
<tr>
<td>7:46</td>
<td>AORTIC DISSECTIONS (5-MINUTE TALKS)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderators: Larry H. Hollier, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Richard P. Cambria, MD</td>
<td></td>
</tr>
<tr>
<td>7:41 -</td>
<td>Future Of Endovascular Treatment Of Ascending Aortic Lesions</td>
<td>Christoph A. Nienaber, MD, PhD</td>
</tr>
<tr>
<td>7:46</td>
<td>Unusual Access Routes To The Ascending Aorta And Arch For Endograft Placement:</td>
<td>Tilo Koelbel, MD, PhD</td>
</tr>
<tr>
<td>7:53 -</td>
<td>Experience With Endograft Treatment Of Ascending Aortic Lesions And Type A</td>
<td>Robert J. Hinchcliffe, MD</td>
</tr>
<tr>
<td>7:58</td>
<td>Dissections</td>
<td>Matt M. Thompson, MD</td>
</tr>
<tr>
<td>7:59 -</td>
<td>Endovascular Graft Treatment Of Type A Dissections: Technique And In What</td>
<td>Zaiping Jing, MD</td>
</tr>
<tr>
<td>8:04</td>
<td>Proportion Of Patients Will It Be Possible</td>
<td></td>
</tr>
<tr>
<td>8:05 -</td>
<td>Complete Endovascular Graft Exclusion Of Arch Aneurysms Using A Non-Custom-Made</td>
<td>Kris si Ivancev, MD, PhD</td>
</tr>
<tr>
<td>8:10</td>
<td>Branched Arch Device (Cook)</td>
<td></td>
</tr>
<tr>
<td>8:11 -</td>
<td>New Developments In Endovascular Repair Of Zone 0 Aortic Arch Pathologies</td>
<td>Toru Kuratani, MD, PhD</td>
</tr>
<tr>
<td>8:16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:17 -</td>
<td>Experience With The Bolton Arch Branch Endograft</td>
<td>W. Anthony Lee, MD</td>
</tr>
<tr>
<td>8:22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:23 -</td>
<td>Advantages Of A Precurved Fenestrated Endograft For Treating Arch Aneurysms</td>
<td>Yoshihiko Yokoi, MD</td>
</tr>
<tr>
<td>8:28</td>
<td>And Dissections</td>
<td></td>
</tr>
<tr>
<td>8:29 -</td>
<td>Hybrid (Open And Endo) Treatment Of Aortic Arch Aneurysms And Dissections:</td>
<td>Roberto Chiesa, MD</td>
</tr>
<tr>
<td>8:34</td>
<td>How Laparoscopy Can Help In Evaluating Patients With Malperfusion</td>
<td>Björn Sonesson, MD, PhD</td>
</tr>
<tr>
<td>8:35 -</td>
<td>Update On In Situ Fenestration For Arch Repair: Will Endovascular Total Arch</td>
<td></td>
</tr>
<tr>
<td>8:40</td>
<td>Repair Replace Open Techniques</td>
<td></td>
</tr>
<tr>
<td>8:41 -</td>
<td>Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>
SESSION 13: PROGRESS IN TREATING DISEASES OF THE THORACIC AORTA, INCLUDING DISSECTIONS AND MANAGING COMPLICATIONS
(5-MINUTE TALKS)

Moderators: Ronald M. Fairman, MD
Christoph A. Nienaber, MD, PhD

8:47 – 8:52
Open Surgical vs. Endovascular Treatment Of Thoracic Aortic Pathology In Marfan's Syndrome: Is Endo Safe And When
Roberto Chiesa, MD

8:53 – 8:58
TEVAR For Type B Aortic Dissections In Marfan's Syndrome Can Work
Chang Shu, MD

8:59 – 9:04
When Is TEVAR Contraindicated And Open Repair Needed With Thoracic Aortic Lesions
Michael J. Jacobs, MD

9:05 – 9:10
What Is In And What Is Out With Type B Aortic Dissections And Their Endovascular Treatment
Zhong Gao Wang, MD

9:11 – 9:16
Long-Term (5-Year) Data On Aortic Remodeling After TEVAR Treatment Of Type B Aortic Dissection Supports Early Intervention
Mark Conrad, MD
Richard P. Cambria, MD

9:17 – 9:22
When Is TEVAR Inadequate Treatment For Type B Aortic Dissections
Götz M. Richter, MD, PhD

9:23 – 9:28
DEBATE: Revascularization Of The Left Subclavian: When It Is Covered During TEVAR Matters: But Only With Aneurysms Not With Dissections
Robert J. Hinchliffe, MD
Matt M. Thompson, MD

9:29 – 9:34
DEBATE: Revascularization Of The Left Subclavian: When It Is Covered During TEVAR Only Matters In Exceptional Circumstances
Thomas S. Maldonado, MD

9:35 – 9:40
DEBATE: Routine Revascularization Of The Left Subclavian For All Zone 2 TEVARs Is Unnecessary And Probably Harmful
Frank J. Criado, MD

9:41 – 9:46
Managing Progression Of Aortic Disease After TEVAR: Open Surgery Will Always Be Needed For Some Thoracic And Thoracoabdominal Aneurysms
Hazim J. Safi, MD

9:47 – 9:54
Panel Discussion
Conclusion Of Program A.

9:54 – 10:10
Break - Visit Exhibits and Pavilions
(2nd and 3rd Floors)

THURSDAY
SESSIONS 13–14

PROGRAM B (SESSIONS 14 – 16)
NEW ENDOVASCULAR APPROACHES TO LOWER EXTREMITY AND BELOW-KNEE ARTERIAL DISEASE AND ITS TREATMENT
(TRIANON BALLROOM, 3RD FLOOR)

6:35 – 6:40
Opening Remarks
Frank J. Veith, MD
SESSION 14 (Trianon Ballroom, 3rd Floor)
LOWER EXTREMITY HOT TOPICS I
(5-MINUTE TALKS)
Moderators: Enrico Ascher, MD
Bruce J. Brener, MD

6:40 – 6:45  DEBATE: 2-3 Year Comparison Of Sirolimus Eluting Stents (SEs) vs. Bare Metal Stents (BMSs) For Below-Knee And Tibial Occlusive Disease (YUKON Trial)
Gunnar Tepe, MD

6:46 – 6:51  DEBATE: Drug Eluting Balloons (DEBs) Are Better For Below-Knee Lesions Than SEs: 1-Year Results
Francesco Liistro, MD

Koen Deloose, MD
Marc Bosiers, MD

6:58 – 7:03  New Developments In Distal Puncture Techniques For Treating CTOs Of Lower Extremity Arteries: The Funnel Balloon Catheter; 3 Fr Sheath; Needle Extensions And COR Balloons
Andrej Schmidt, MD

7:04 – 7:09  Best Treatment Of Popliteal Lesions: Stent vs. PTA: The ETAP Trial
Thomas Zeller, MD

7:10 – 7:15  Value Of The Biodegradable Balloon Expandable Remedy Stent For Lower Extremity Lesions: The GAIA Trial Results
Dierk Scheinert, MD

7:16 – 7:21  Does Atherectomy Help To Treat Resistant Calcified SFA Lesions: Does It Require A Distal Filter For Safety
Daniel G. Clair, MD

7:22 – 7:27  DEBATE: Current Role Of New Atherectomy Devices: They Work And Justify The Costs
James F. McKinsey, MD

7:28 – 7:33  DEBATE: Debunking With Atherectomy And Laser Is A Good Idea Whose Time Has Passed
Frank J. Criado, MD

7:34 – 7:40  Panel Discussion

SESSION 15 (Trianon Ballroom, 3rd Floor)
LOWER EXTREMITY HOT TOPICS II
(5-MINUTE TALKS)
Moderators: Kenneth Ouriel, MD, MBA
Evan C. Lipsitz, MD

7:40 – 7:45  Long-Term Evaluation (To 5 Years) Of SFA Stents In 1000 Patients: Importance Of TASC Classification, Stent Type And Lesion Length (Belgian/German Study)
Marc Bosiers, MD
Giovanni Torsello, MD
Patrick Peeters, MD

7:46 – 7:51  The Many Uses And Advantages Of The Supera Veritas Stent (IDEV) To Treat Femoropopliteal Lesions
Peter C.J. Goverde, MD
Dierk Scheinert, MD
1-Year Results Of The Protege Everflex Stent (ev3) To Treat Popliteal Lesions: DURABILITY-POP Study
Patrick Peeters, MD

DEBATE: CFA And DFA Occlusive Lesions Are Best Treated By Endovascular Techniques
Thomas Zeller, MD

DEBATE: How Should CFA And DFA Occlusive Lesions Best Be Treated
Gustavo S. Oderich, MD

Extreme Approaches To CTOs via Retrograde Puncture Of Pedal Loop And Digital Arteries: How To Do It
Marco G. Manzi, MD

DEBATE: Stenting Is Still First Line Treatment For SFA Occlusive Disease
Erich Minar, MD

DEBATE: Why Should Metal Be Avoided In The SFA And How To Do It
Giancarlo Biamino, MD, PhD

How To Remove Small Procedural Emboli From Tibial Arteries
Andrej Schmidt, MD

What To Do For CLI Patients When There Are No Patent Outflow Arteries: Can DEBs Help
Roberto Ferraresi, MD

Panel Discussion

SESSION 16 (Trianon Ballroom, 3rd Floor)
LOWER EXTREMITY HOT TOPICS III
(5-MINUTE TALKS)

Moderators: Jacques Busquet, MD
Luis A. Sanchez, MD

DEBATE: Atherectomy And DEBs For Native Disease And In Stent Restenosis In The SFA And Popliteal: Stents Can Be Avoided Completely
Thomas Zeller, MD

DEBATE: DEBs Won’t Do The Job Alone: Stents Will Be Needed Sometimes For Recoil Or Dissection
Dierk Scheinert, MD

The Tack-It Device: An Endovascular Stapler For Imperfect PTAs To Avoid Stenting
Peter A. Schneider, MD

3-Year Results Of The RESILIENT Trial With The Lifesent: Are The Results Of SFA Stents Durable
John R. Laird, MD

3-Year Results From The ZILVER PTX Drug Eluting Stent (DES) Trial: Are The Results Durable And How Do Patterns Of Restenosis Differ
Michael D. Duke, MD
Gary M. Ansel, MD

2-Year Outcomes Of Stent Supported PTA For Iliac Lesions: Balloon vs. Self-Expanding Stents: Influence Of TASC Classification: The BRAVISSIMO Trial
Patrick Peeters, MD

DEBATE: To Treat Lower Extremity Chronic Total Occlusions (CTOs) One Only Needs A Wire And A Catheter And Not All This Expensive Nonsense
Amman Bolia, MD
NEW DEVELOPMENTS IN SFA AND CRURAL ARTERY TREATMENT OF CRITICAL LIMB ISCHEMIA (CLI) (5-MINUTE TALKS)

Moderators: Frank J. Veith, MD
Barry T. Katzen, MD

10:10 – 10:15
Why Is Duplex For Guidance For Lower Extremity Endovascular Procedures Not Replacing Fluoroscopy: Duplex Is So Much Better
Enrico Ascher, MD

10:16 – 10:21
13 Steps To Successful Pedal Access
Craig M. Walker, MD

10:22 – 10:27
Drug Eluting Balloons (DEBs) Really Work: Comparative Results Prove It: When And Where Are DEBs Indicated
Gunnar Tepe, MD

10:28 – 10:33
How Have DEBs Changed Lower Extremity Interventional Practice In Germany: Above And Below The Knee
Andrej Schmidt, MD

10:34 – 10:39
How DEBs Have Changed Lower Extremity Interventional Practice In Italy: Are They Worth The Increased Cost
Giancarlo Biamino, MD, PhD

10:40 – 10:45
Drug-Eluting Stents For Focal Infrapopliteal Lesions: Meta-Analysis Of The ACHILLES, DESTINY And YUKON-BTX Trials
Konstantinos Katsanos, MSc, MD, PhD

10:46 – 10:51
Differences In Amputation Rates Following Treatment For Tissue Loss (Gangrene) And Rest Pain: Their Importance In Trials Evaluating Stem Cell And Other New Treatments
Thomas F. O’Donnell, Jr., MD

10:52 – 10:57
Why Are DESs Not Going To Work In CLI Patients Based On The Anatomy Of Their Lesions
Nicholas A. Diehm, MD

10:58 – 11:03
The Case For Subintimal PTA Above And Below The Inguinal Ligament
George H. Meier III, MD
Open Bypass Procedures Have Value And Can Work When Endovascular Interventions Have Failed: What Percentage Of CLI Patients Will Need A Bypass: Endo First Is Not The Way To Go In Some Patients Since Bridges Are Burned
Francesco Spinelli, MD

Pedal Bypasses Are Definitely Superior To PTA For Long Tibial Lesions
Werner Lang, MD

Wound Related And Flow Guided Treatment For CLI With Necrotic Foot Lesions
Roberto Ferraresi, MD

DEBATE: The Case For The Angiosome Concept
Richard F. Neville, MD

DEBATE: The Angiosome Concept Is Not Important Except Possibly In Dialysis Patients
Nobuyoshi Azuma, MD

DEBATE: A Patent Pedal Arch Is More Important Than The Angiosome Concept: But Foot Healing Can Occur Without An Intact Pedal Arch
Hisham Rashid, MSc

Indocyanine Green Angiography: A Method To Study The Angiosome Concept
Joseph L. Mills, MD

Stem Cell Therapy Will Have An Increasing Role In The Treatment Of CLI: It Really Works And A Glimpse Into The Future: Based On The RESTORE CLI Phase 2b Trial
Richard J. Powell, MD

Panel Discussion

Lunch Break - Americas Hall I, 3rd Floor
Visit Exhibits and Pavilions (2nd and 3rd Floors)

CONCURRENT THURSDAY AFTERNOON PROGRAMS (1:00 P.M. – 6:55 P.M.)

PROGRAM C
(SESSIONS 18 – 22)
TEVAR, EVAR (18); Carotid Stenting (19); (20) Lower Extremity Stent-Graft; Vascular Disease And CCSVI For MS (21); Endoleaks (22)
1:00 P.M. – 6:55 P.M.
Grand Ballroom East, 3rd Floor

PROGRAM D
(SESSIONS 23 – 25)
Short Topics Relevant To Other Parts Of Program C On Lower Extremity (23); Thoracic And Abdominal Aorta (24); Miscellaneous And CCSVI (25)
1:00 P.M. – 5:45 P.M.
Grand Ballroom West, 3rd Floor

PROGRAM C (SESSIONS 18 – 22)
SESSION 18 (GRAND BALLROOM EAST, 3RD FLOOR)
NEW DEVELOPMENTS IN TEVAR AND EVAR (5-MINUTE TALKS)

Moderators: Juan C. Parodi, MD
Hazim J. Safi, MD

1:00 – 1:05
Axillofemoral Bypass To Prevent Limb Ischemia During Prolonged Iliac Sheath Occlusion For Complex EVARs
Krassi Ivancev, MD, PhD

1:06 – 1:11
Lessons Learned And Precautions Needed With Fenestrated And Branched Grafts For Complex Aneurysm Repairs
Piotr M. Kasprzak, MD

1:12 – 1:17
Pathogenesis Of Spinal Cord Ischemia (SCI) During TEVAR And Open Repair: Is It The Same Or Different: Implications For Prevention And Treatment
Charles W. Acher, MD

1:18 – 1:23
How To Prevent SCI After TEVAR
Michael J. Jacobs, MD

1:24 – 1:29
Tips And Tricks For Performing CSF Drainage Optimally With TEVAR Or Open Repair
Vicente Riambau, MD, PhD

1:30 – 1:35
DEBATE: Endovascular Graft Treatment Of Acute Uncomplicated Type B Aortic Dissection May Not Be A Good Idea: Medical Treatment May Be As Good (Video)
Sebastian E. Debus, MD, PhD

1:36 – 1:41
DEBATE: Experience With Early TEVAR Treatment Of Uncomplicated Type B Aortic Dissection: It Really Is The Right Thing To Do Based On False Lumen/True Lumen Measurements
Rodney A. White, MD

1:42 – 1:47
Long-Term (3–5 Year) Results Of The INSTEAD Trial Shows The Benefit Of Early TEVAR Treatment Of Uncomplicated Type B Aortic Dissections: Game Changing Results
Christoph A. Nienaber, MD, PhD

1:48 – 1:53
Results Of TEVAR In Acute Type B Aortic Dissection vs. Best Medical Treatment: First Results Of The ADSORB Trial: A Randomized Controlled Trial
Jan S. Brunkwall, MD, PhD

1:54 – 1:59
Some Concerns After Aortic Endografting For Type B Aortic Dissections
Stephen W.K. Cheng, MBBS

2:00 – 2:05
How Valuable Are The Aptus HeliFX Staples (EndoAnchors): Results From The ANCHOR Registry
William D. Jordan, Jr., MD

2:06 – 2:12
Panel Discussion

SESSION 19 (Grand Ballroom East, 3rd Floor)

CRITICAL EVALUATION OF CAROTID ARTERY STENTING (CAS) IN NOVEMBER 2012: WHERE IS IT AND WHERE IS IT GOING (5-MINUTE TALKS)

Moderators: Giorgio M. Biasi, MD
Frank J. Veith, MD

2:12 – 2:17
Why MRI Should Be Done Before All Revascularization Procedures (CAS And CEA): Duplex Is Not Enough
Emmanuel M. Houdart, MD
Closed vs. Open Cell Stents For CAS: The Number Of Embolic Particles Are No Greater Nor Are Outcomes Worse With Open Cell Stents
Peter L. Faries, MD

CAS For Total Carotid Occlusion: It Can Work And Be Beneficial: Under What Circumstances
Paul H.L. Kao, MD

DEBATE: CAS Is Good Treatment For Most Patients With Symptomatic And Asymptomatic Carotid Stenosis
Klaus D. Mathias, MD

DEBATE: CAS Is Not Good Treatment For Most Patients With Symptomatic And Asymptomatic Carotid Stenosis
Bruce A. Perler, MD, MBA

Is Current Best Medical Treatment (BMT) Feasible And Does It Work To Decrease Strokes From Intracranial Disease In A High Risk Population: Results From The SAMMPRIS Trial Suggest BMT Can Decrease Strokes Markedly
Marc Chimowitz, MD

Analysis Of CREST By A Neuroradiologist: What Is The Significance Of A Minor Stroke
Emmanuel M. Houdart, MD

DEBATE: Cardiac Events Are An Appropriate End-Point For Evaluating CAS vs. CEA Outcomes; And In CREST, CAS Results Improved With Time
William A. Gray, MD

DEBATE: Cardiac Events Are Not An Appropriate End-Point For Evaluating CAS vs. CEA Outcomes; And In CREST, CAS Results Did Not Improve With Time
Wesley S. Moore, MD

Interventions Performed Within 1 Week Of A Neurological Event: Outcomes Of CEA Are Better Than CAS
Hans-Henning Eckstein, MD, PhD

The Case Against Embolic Protection Devices In CAS: Why Therefore Are They So Widely Used
Michel S. Makaroun, MD

Meta-analysis Of CAS By Cervical Access Shows Dramatic Reduction In Neurological Events
Patrice F. Bergeron, MD Petrosian Andranik, MD

A Specialized Device For Performing CAS Via A Cervical Approach With Flow Reversal (FAST-CAS System): Early Results From The PROOF Trial
Ralf R. Kolvenbach, MD

DEBATE: Why Is It Difficult To Randomize Asymptomatic Carotid Stenosis Patients To A 3-Armed Trial: CEA vs. CAS vs. BMT Hans-Henning Eckstein, MD, PhD

DEBATE: Why We Must Have A Trial Comparing BMT To CAS And CEA In Asymptomatic Patients With Carotid Stenosis
Anne L. Abbott, MD, PhD

TCD Embolic Signals, Silent Infarcts On CT-Brain Scans, Or The Size Of Juxtaluminal Black Area In Evaluating Stroke Potential Of Asymptomatic Carotid Lesions
Andrew N. Nicolaides, MS
SESSION 20 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN LOWER EXTREMITY STENT-GRAFTS (5-MINUTE TALKS)
Moderators: Mark A. Adelman, MD
Darren B. Schneider, MD

3:48 – 4:00
Panel Discussion And Break
Visit Exhibits and Pavilions (2nd and 3rd Floors)

4:00 – 4:05
Patency Of Viabahn Stent Grafts Is Better Than Bare Metal Stents For SFA Occlusive Disease: Final Results Of The VIASTAR Trial
Johannes Lammer, MD

4:06 – 4:11
Are Stent Grafts The Solution For In-Stent Restenosis After SFA Stenting
Marc Bosiers, MD
Koen Deloose, MD

4:12 – 4:17
Technical Considerations To Improve Results With SFA Stent-Grafting For Occlusive Disease: Lessons Learned From The VIPER Trial With Heparin-Bonded Viabahn Stent-Grafts
Richard R. Saxon, MD

4:18 – 4:23
Why Do Viabahn Stent-Grafts Fail In The First Year: Does Collateral Coverage And Antiplatelet Treatment Matter
Michael S. Conte, MD

4:24 – 4:29
Standard Fempop Bypasses Are Better Than Endoluminal Stent-Graft "Bypasses" For 5-25 cm SFA Occlusions: An Older RCT: Is It Still Relevant
Mauri J.A. Lepantalo, MD

4:30 – 4:35
Current Status Of Heparin Bonded Viabahn Stent-Grafts Based On European Studies
Thomas Zeller, MD

4:36 – 4:41
Current Status Of Viabahn Endografts For Treatment Of Popliteal Aneurysms: Which Patients Should Not Be Treated Endovascularly
Eric L.G. Verhoeven, MD, PhD

4:42 – 4:47
Can Covered Stents Safely Be Placed Across The Inguinal Ligament And In The CFA
Keith D. Calligaro, MD

4:48 – 4:55
Panel Discussion

SESSION 21 (Grand Ballroom East, 3rd Floor)
NEW OR IMPROVED CONCEPTS IN VASCULAR DISEASE TREATMENT AND THE CONTROVERSY OVER THE INTERVENTIONAL TREATMENT OF CCSVI FOR MULTIPLE SCLEROSIS (5-MINUTE TALKS)
Moderators: Bruce A. Perler, MD, MBA
Jean-Baptiste Ricco, MD, PhD

4:55 – 5:00
Tips And Tricks For Vascular Disease Intervention In Pediatric Patients
Furuzan Numan, MD

5:01 – 5:06
DEBATE: Update On The Treatment Of Vasculogenic Impotence: Viagra, Cialis And Levitra Are Most Often Enough
Ralph G. DePalma, MD

5:07 – 5:12
DEBATE: Not True, Some Patients Need Internal Pudendal Stenting: Current Status Of The Endovascular Treatment Of Erectile Dysfunction
Krishna J. Rocha-Singh, MD
The CCSVI Controversy In Multiple Sclerosis

5:13 – 5:18
What’s New In The Diagnosis And Endovascular Treatment Of CCSVI In MS Patients
Paolo Zamboni, MD

5:19 – 5:24
Endovascular Treatment Of CCSVI In MS Patients Really Works: The Benefits Of Treating Venous Brain Congestion Can Be Documented
Ivo Petrov, MD, PhD

5:25 – 5:30
Does Interventional Treatment Help MS Patients: A Skeptical Vascular Surgeon Remains Skeptical
Jean-Baptiste Ricco, MD, PhD

5:31 – 5:36
Intrinsic And Extrinsic Cerebrospinal Venous Abnormalities In Neurological Diseases: Anatomic And Physiological Evidence
Michael D. Dake, MD

5:37 – 5:42
Interventional Treatment Of CCSVI Can Improve MS: A Vascular Surgeon Who Is Convinced
Manish Mehta, MD, MPH

5:43 – 5:48
DEBATE: The Case Against Treating CCSVI In MS Patients
Emmanuel M. Houdart, MD

5:49 – 5:54
DEBATE: The Case For Treating CCSVI In MS Patients
Donald B. Reid, MD

5:55 – 6:00
DEBATE: Venous Angioplasty For MS Is Voodoo Medicine
Mark H. Wholey, MD

6:01 – 6:06
Panel Discussion

SESSION 22 (Grand Ballroom East, 3rd Floor)
NEW OR BETTER TECHNIQUES FOR TREATING ENDOLEAKS AND OTHER EVAR AND TEVAR TOPICS (5-MINUTE TALKS)
Moderators: Timur P. Sarac, MD Luis A. Sanchez, MD

6:06 – 6:11
How And When Is It Safe To Treat Type I Endoleaks After EVAR Non-Interventionally: A 13-Year Experience
James May, MD, MS

6:12 – 6:17
How Embolization With Onyx Can Be An Effective Solution For Type I Endoleaks And Other Novel Solutions For Endoleaks After EVAR And TEVAR
Robert A. Morgan, MD

6:18 – 6:23
Long-Term Follow-up Of Treated Type II Endoleaks Shows The Need For Close Surveillance And Frequent Re-Treatment
Timur P. Sarac, MD

6:24 – 6:29
When Does Translumbar Glue Embolization Of Type II Endoleaks Work And When Does It Not: Tips And Tricks To Make It Effective
Neal S. Cayne, MD

6:30 – 6:35
Tips And Tricks On How To Use Onyx In The Treatment Of Type I And Other Major Endoleaks
Thomas Larzon, MD

6:36 – 6:41
The Anaconda Fenestrated Graft For Juxtarenal AAAs: Advantages, Limitations And 1-Year Registry Results
Nick J. Burfitt, BSc, MB, BChir, MRCS
Interplay Between Anatomy And Indications (Pathology) In TEVAR Outcomes: Anatomic Complexity Drives Outcomes More Than Indications (Pathology)

Michael C. Stoner, MD

Panel Discussion
Conclusion of Program C.

PROGRAM D (SESSIONS 23 – 25)
SHORT TOPICS RELEVANT TO OTHER PARTS OF THE PROGRAM ON LOWER EXTREMITY, THORACIC AND ABDOMINAL AORTA; MISCELLANEOUS AND CCSVI (GRAND BALLROOM WEST, 3RD FLOOR)

SESSION 23 (Grand Ballroom West, 3rd Floor)
LOWER EXTREMITY ADDITIONAL TOPICS (4-MINUTE TALKS)
Modérators: Peter L. Faires, MD Ross Milner, MD

1:00 – 1:04 Bringing Atherectomy To The Next Level: What Is Its Future
Jos C. van den Berg, MD, PhD

1:05 – 1:09 Optical Coherence Tomography Of The Femoral Arteries: How Is It Done And What Is Its Value
Konstantinos Katsanos, MSc, MD, PhD

1:10 – 1:14 Will Plaque Excision By Atherectomy Become The Treatment Of Choice For Popliteal Occlusive Disease: 1-Year Results From The DEFINITIVE LE Trial In 800 Patients
James F. McKinsey, MD

1:15 – 1:19 The True Path Rotating Tip Device For Crossing Chronic Total Occlusion (CTO): How Does It Work And How Well Does It Work
John R. Laird, MD

1:20 – 1:24 Relevance Of In-Stent Restenosis In Various Territories And Best Strategies For Treatment
John R. Laird, MD

1:25 – 1:29 Laser Debubling And DEB For In-Stent Restenosis
Jos C. van den Berg, MD, PhD

1:30 – 1:34 The Wildcat Catheter From Avinger In Crossing Difficult Aortoiliac Occlusions
Patrick E. Muck, MD

1:35 – 1:39 Status Of Biodegradable Stents And Will They Work In The Periphery
Ron Waksman, MD

1:40 – 1:44 Long-Term Results Of The ABSORB Trial Showing Benefits Of Biodegradable Coronary Stents: When Will We Know If They Will Work Elsewhere
Lewis B. Schwartz, MD

1:45 – 1:49 Heparin Bonded Bypass Grafts, Stent-Grafts And Hybrid Grafts: Will They Make A Difference
Edward Y. Woo, MD

1:50 – 1:54 Improved 3-Year Patenty Of Heparin Bonded PTFE Grafts vs. PTFE Grafts Without Heparin
Russell H. Samson, MD, RVT

1:55 – 1:58 Best Treatment For In-Stent Restenosis After Renal Artery Stenting
Robert A. Lookstein, MD

2:00 – 2:04 Current Optimal Treatment For Long SFA Occlusions
Gary M. Ansel, MD
Tips And Tricks For Successful Stent-Graft Treatment Of Popliteal Aneurysms
Irwin V. Mohan, MD

Is Functional Popliteal Entrapment A Myth Or Reality
Cynthia K. Shortell, MD

Prior Contralateral Major Amputation Predicts Worse Outcomes For Lower Extremity Revascularization In The Intact Limb
Andres Schanzer, MD

Outcomes Of Single Segment Greater Saphenous Vein Graft Bypasses Are Better Than Those Of Alternative Autologous Vein Bypasses
Mauri J.A. Lepantalo, MD

Panel Discussion

How Much Does Stent Design Matter For The Various Thoracic Aortic Pathologies: What Are The Unmet Needs
Michael D. Dake, MD

Initial Experience With Ascending Aortic Endografting Using The Cook Endograft For Type A Dissection
Ralf R. Kolvenbach, MD

Do Distal Bare Stents Have Value In The Treatment Of Type B Aortic Dissections
Burkhart Zipfel, MD

The Embrella Aortic Arch Embolic Deflector: Does It Work: What Precautions Must Be Used And What Are Its Complications
Jeffrey P. Carpenter, MD

New Classification System For Blunt Traumatic Aortic Injury To Guide In Conservative Or Endograft Treatment
Benjamin W. Starnes, MD

Pros And Cons Of Early TEVAR With Extensive Coverage Of The Thoracic Aorta In Type B Aortic Dissections
Frank J. Criado, MD

Diagrams Showing How To Make Sandwich Grafting Technique Work For Endovascular Treatment Of Thoracoabdominal Aneurysms
Armando C. Lobato, MD, PhD

How Do Pressure Changes In The Excluded Aneurysm Sac Impact On Spinal Cord Ischemia After TEVAR
Björn Sonesson, MD, PhD

How Do Outcomes From A Contemporary EVAR Registry (ENGAGE Registry) Differ From Those From Older Registries Like EUROSTAR: EVAR Is Getting Better
Marc R.H. van Sarnbeek, MD, PhD

Decreasing Prevalence Of AAAs And Improving Short-Term And Long-Term Outcomes After EVAR In Sweden: What Are The Reasons For Them
Anders Wanhainen, MD, PhD
Martin Björck, MD, PhD

SESSION 24 (Grand Ballroom West, 3rd Floor)
ADDITIONAL THORACIC AND ABDOMINAL AORTA TOPICS (4-MINUTE TALKS)
Moderators: Jerry Goldstone, MD
Gary Giangola, MD

How Much Does Stent Design Matter For The Various Thoracic Aortic Pathologies: What Are The Unmet Needs
Michael D. Dake, MD

Initial Experience With Ascending Aortic Endografting Using The Cook Endograft For Type A Dissection
Ralf R. Kolvenbach, MD

Do Distal Bare Stents Have Value In The Treatment Of Type B Aortic Dissections
Burkhart Zipfel, MD

The Embrella Aortic Arch Embolic Deflector: Does It Work: What Precautions Must Be Used And What Are Its Complications
Jeffrey P. Carpenter, MD

New Classification System For Blunt Traumatic Aortic Injury To Guide In Conservative Or Endograft Treatment
Benjamin W. Starnes, MD

Pros And Cons Of Early TEVAR With Extensive Coverage Of The Thoracic Aorta In Type B Aortic Dissections
Frank J. Criado, MD

Diagrams Showing How To Make Sandwich Grafting Technique Work For Endovascular Treatment Of Thoracoabdominal Aneurysms
Armando C. Lobato, MD, PhD

How Do Pressure Changes In The Excluded Aneurysm Sac Impact On Spinal Cord Ischemia After TEVAR
Björn Sonesson, MD, PhD

How Do Outcomes From A Contemporary EVAR Registry (ENGAGE Registry) Differ From Those From Older Registries Like EUROSTAR: EVAR Is Getting Better
Marc R.H. van Sarnbeek, MD, PhD

Decreasing Prevalence Of AAAs And Improving Short-Term And Long-Term Outcomes After EVAR In Sweden: What Are The Reasons For Them
Anders Wanhainen, MD, PhD
Martin Björck, MD, PhD
What Is The Annual Rupture Risk Of AAAs That Have Increasing Sac Size After EVAR But No Detectable Endoleak

Frans L. Moll, MD, PhD

How Well Are The Complex (Fenestrated) Stent-Grafts Doing: UK Multicenter Study

S. Rao Vallabhaneni, MD
Richard G. McWilliams, MD

Optimal Current Treatment Of Infected AAAs: The Role Of Endografts

Kamphol Laophapensang, MD

1-Day Surgery For EVAR: Experience In >60 Patients

Zoran Rancic, MD, PhD

How Well Do Endografts Do In The Treatment Of Aortoduodenal And Aortoesophageal Fistulas: How Can Survival Be Achieved

Bart E. Muhs, MD, PhD

Tips And Tricks For Managing Difficult Iliac Arteries: Tug-Wire Technique To Overcome Tortuous Arteries And Balloon Slide Technique To Overcome Tiny Arteries

Thomas Larzon, MD

The CCSVI Controversy In Multiple Sclerosis

Creation Of A New IVC In A Patient Whose IVC Was Obliterated By Trauma: An Interventional Approach

Thomas A. Sos, MD
Akhilesh Sista, MD

What’s Happening To The Randomized Trials Comparing Interventional Treatment To Placebo Treatment Of CCSVI In MS Patients

L. Nelson Hopkins, MD

Incidence Of Internal Jugular Vein Stenosis In Thoracic Outlet Syndrome Patients: How Does This Relate To MS And CCSVI

Sam S. Ahn, MD, MBA

Are Venous Anomalies In MS Patients Relevant Or Not

Alan H. Davies, MA, DM

MS And CCSVI: Is The Relationship Real And Causally Important

Andrew N. Nicolaides, MS

Improving Contemporary Usage And Techniques Result In Better Patency With Nitinol SFA Stents (Smart Stents): Based On The STROLL Trial

Marc H. Glickman, MD

More About Abdominal And Thoracoabdominal Aneurysms

New Classification Of Suprarenal Aneurysms Based On Location Of The Proximal Seal Zone: Correlates With Mortality And Morbidity Of Fenestrated And Branched Endografts

Kamphol Laophapensang, MD

SESSION 25 (Grand Ballroom West, 3rd Floor)
MISCELLANEOUS IMPORTANT TOPICS
(4-MINUTE TALKS)

Moderators: Michael D. Dake, MD
Krassi Ivancev, MD, PhD

Panel Discussion

SESSIONS 24–25
Is Medical Treatment To Slow Growth Of AAAs
Effective: The STOPS Trial
Ronald L. Dalman, MD

An Improved Method For Measuring AAA Size With
EKG Gated 3D Ultrasound
Henrik Sillesen, MD, DMSc

What Is The “Best” Treatment For Perigraft Hygroma
With AAA Sac Enlargement After EVAR
John Blebea, MD, MBA

Novel Method For Making Cannulation Of The
Contralateral Limb Quick (<10 Seconds) And Easy
During EVAR
Willem Wisselink, MD

Panel Discussion

Miscellaneous Topics

Moderators: John B. Chang, MD
Elliot L. Chaikof, MD, PhD

What Will Happen In The Effort To Separate
Doctors From Industry: Predictions For The Future
And What Is Happening In Massachusetts
Richard A. Baum, MD, MPA, MBA

Principles Of “Best” Medical Treatment To Prevent
Stroke
Anne L. Abbott, MD, PhD

Managing Complications Of CAS
Klaus D. Mathias, MD

Stroke Prevention And PFO Closure: Dead Or Alive
William A. Gray, MD

Catheter Directed Thrombolysis As Treatment For
Acute SMA Occlusion
Björn Sonesson, MD, PhD
Martin Björck, MD, PhD
Timothy A. Resch, MD, PhD

Novel Endovascular Techniques For Treating Complex
Iliac Aneurysmal Disease
Joseph L. Mills, MD
Luis R. Leon, MD, RVT

Laparoscopic Sutureless Aortobifemoral Bypass Using
The Lachat Viabahn (VORTEC) Technique
Ralf R. Kolvenbach, MD

How Do Long Bare Metal SFA Stents Perform: The
DURABILITY Trial Clinical Outcomes, Treadmill
Data, Objective Patency, And Routine Stent Fracture
Assessment
Jon S. Matsamura, MD

Homocysteine Is A Predictor Of Vascular Mortality: A
Useful Marker Misunderstood
Afshin Assadian, MD

Use Of Duplex Ultrasound To Facilitate Distal Tibial
And Pedal Access To Treat Lower Extremity Occlusive
Disease
Jihad A. Mustapha, MD

Panel Discussion
Conclusion of Program D.
CONCURRENT FRIDAY MORNING PROGRAMS

PROGRAM E (SESSIONS 26 – 29)

New Techniques And Technologies (26); TAAAs And CHIMPS (27); Lower Extremity Ischemia – CLI (28); Medical Therapy And Medical Problems (29)

6:40 A.M.– 12:00 P.M.
Grand Ballroom East, 3rd Floor

PROGRAM F (SESSIONS 30 – 32)

Miscellaneous Hot Topics Related To Lower Extremity And Aortic Disease (30); Venous Topics (31-32)

6:45 A.M. – 12:00 P.M.
Grand Ballroom West, 3rd Floor

PROGRAM E (SESSIONS 26 – 29)
(GRAND BALLROOM EAST, 3RD FLOOR)

SESSION 26
(Grand Ballroom East, 3rd Floor)

NEW TECHNIQUES AND NEW ENDOVASCULAR TECHNOLOGY (5-MINUTE TALKS)

Moderators: Nicholas J. Morrissey, MD
Michael L. Marin, MD

6:40 – 6:45 Use Of Microbubbles In The Treatment Of Acute Arterial Occlusions: How Do They Work And Do They Have Clinical Value
Willem Wisselink, MD

6:46 – 6:51 How The Art-Assist Pneumatic Compression Device Can Heal Ulcers From CLI And Relieve Rest Pain Noninvasively
Andrew N. Nicolaides, MS

6:52 – 6:57 A New Device For Topical Intermittent Compression And Hyper-Oxygenation To Improve Healing Of Infected Ischemic Foot Wounds
Magdiel Trinidad-Vasquez, MD

Christopher J. Kwolek, MD
Richard P. Cambria, MD

7:04 – 7:09 Use Of Pressure Wire And CO2 Angiography To Make Renal Artery Stenting Safer And Better
Kim J. Hodgson, MD

7:10 – 7:15 Predicting The Results Of Interventional Treatment Using Computational Analysis Of Blood Flow And Lesion Resistance From CT Data: Is FFR (Fractional Flow Reserve) Applicable To Peripheral Arteries As Well As Coronaries
Christopher K. Zarins, MD

7:16 – 7:21 Progress In Techniques For Treating Below-Elbow Occlusions For Critical Hand Ischemia
Roberto Ferraresi, MD
SESSION 27 (Grand Ballroom East, 3rd Floor)
THORACOABDOMINAL AORTIC ANEURYSMS (TAAAs) AND TECHNIQUES TO REVASCULARIZE RENAL AND VISCERAL ARTERIES: CHIMNEYS, PERISCOPES AND SANDWICH GRAFTS (CHIMPS) (5-MINUTE TALKS)

Moderators: Mark A. Adelman, MD
Frank J. Veith, MD

7:33 – 7:38
Why Parallel Grafts (CHIMPS) Work And Why A Double D Configuration Can Be Achieved With Elimination Of Gutter Endoleaks: Theoretical Considerations And How To Calculate The Right Sizes Of The Parallel Grafts
Jerry Matteo, MD

7:39 – 7:44
Long-Term Results After Chimney And Periscope Grafts Up To 7 Years: Are They Durable And How To Make Them Work Well For Pararenal And TAAAs
Mario Lachat, MD
Dieter O. Mayer, MD
Zoran Rancic, MD, PhD

7:45 – 7:50
Tips And Tricks For Getting Good Results With CHIMPS: When Fenestrated vs. When CHIMPS
Giovanni Torsello, MD
Konstantinos Donas, MD

7:51 – 7:56
Long-Term Results After Sandwich Grafts For TAAAs: Where And When Do They Work And What Precautions Must Be Taken
Armando C. Lobato, MD, PhD

7:57 – 8:02
When Do Chimneys Work And When Don’t They: Experience In >140 Patients
Thomas Larzon, MD

8:03 – 8:08
How To Repair Juxtarenal AAAs Safely And Effectively With Double Chimney Grafts: Technique And Results
Jason T. Lee, MD
Ronald L. Dalman, MD

8:09 – 8:14
Branched And Fenestrated Grafts Are Best: But What TAAAs Can’t Be Treated With Them And Can Sandwich Grafts Solve The Problem
Martin Malina, MD, PhD

8:15 – 8:20
DEBATE: CHIMPS Are Better And Cheaper Than Branched And Fenestrated Grafts For Treating Complex Aneurysms: CHIMPS Will Always Have A Major Role
Ralf R. Kolvenbach, MD

8:21 – 8:26
DEBATE: CHIMPS Are Inferior To Branched And Fenestrated Grafts For Complex Aneurysms: Long-Term Results Will Prove It: CHIMPS Will Have Only A Minor Role
Stephan Haulon, MD

8:27 – 8:32
Fenestrated And Branched Grafts For EVAR - How Well Have They Performed In France When Used Widely: Based On A National Audit: How These Results Compare With Those Of The Cardiatis Multilayer Stent For Similar Lesions
Jean-Pierre Becquemin, MD
Role Of Endo, Open And Hybrid For TAAAs: When Is Open Repair Still Best
Michael J. Jacobs, MD

Advanced Techniques For Performing EVAR With Difficult Anatomy: How To Avoid Brachial Access When Placing Chimney Or Periscope Grafts
David J. Minion, MD

Off-The-Shelf Bifurcated EVAR Grafts For TAAAs: Does It Hold Up And How To Get A Double D Configuration With Seal Of Parallel Grafts
Karthikeshwar Kasirajan, MD

Late Results With Physician Modified Stent Grafts For Pararenal And TAAAs: They Are As Good As Manufactured Grafts If . . .
Gustavo S. Oderich, MD

A New Simpler Device For Juxtarenal AAAs
Marcelo Ferreira, MD

SESSION 28 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN THE TREATMENT OF LOWER EXTREMITY ISCHEMIA AND CLI (5-MINUTE TALKS)
Moderators: Peter F. Lawrence, MD Gregg S. Landis, MD

Long-Term Results With Drug Eluting Balloons (DEBs): Summary Of The Available Trials With Up To 5-Year Results Of THUNDER, DEBATE And PACIFIER Trials With Paclitaxil Coatings
Gunnar Tepe, MD

Long-Term (2-5 Years) Results Of SFA Stent Performance In 1000 Patients (A Belgium/Germany Registry Report)
Giovanni Torsello, MD Marc Bosiers, MD

Promising 1-Year Patency Results For A New Prosthetic Graft (The Fusion Graft) For Above Knee Femoropopliteal Bypass: The PERFECTION Trial
Hans-Henning Eckstein, MD, PhD Afshin Assadian, MD

Extremity Arterial Reconstruction In Children: Tips And Precautions
James C. Stanley, MD Jonathan Eliason, MD

DEBATE: All CLI Patients Should Be Treated First By Endovascular Techniques
Gary M. Ansel, MD

DEBATE: Some CLI Patients Should Be Treated By A Bypass First: Which Ones And Has Anything Changed In The Past Year
Michael S. Conte, MD

Pros And Cons Of Bypass And PTA For Treatment Of Intermittent Claudication From SFA Occlusive Disease: Does Bypass Still Have A Role
Marc L. Schermerhorn, MD

Endovascular Treatment Of Infrainguinal Bypass Failure And Impending Failure
Nicholas A. Diehm, MD
SESSION 29 (Grand Ballroom East, 3rd Floor)
ADVANCES IN MEDICAL THERAPY OR TREATMENT OF MEDICAL PROBLEMS OR COMPLICATIONS (5-MINUTE TALKS)

Moderators: Anton N. Sidawy, MD, MPH Plinio Rossi, MD

10:45 – 10:50 Platelet Activity And Optimizing Antiplatelet Treatment: The Next Frontier In Vascular Disease Management Jeffrey S. Berger, MD, MS

10:51 – 10:56 What’s New With Endovascular Ablation Procedures For Atrial And Ventricular Arrhythmias Larry Chinitz, MD


11:03 – 11:08 What’s All This Hoopla About Statins And Mental Fogginess, Increased Blood Sugar And Diabetes: Should It Make A Difference In Statin Usage Or Is It A Witch Hunt Don Poldermans, MD

11:09 – 11:14 New Concepts Regarding The Importance Of Plaque Instability And Stability In Coronary And Vascular Disease: How Instability Should Be Determined And Treated Gregg W. Stone, MD

11:15 – 11:20 High Incidence Of Asymptomatic Elevated Troponin Levels (Troponin-Only MIs) After Open Vascular Surgery: What Does It Mean And What Can Be Done To Decrease It Carson B. Rockman, MD

11:21 – 11:26 DEBATE: Why We Should Not Stop Screening For Asymptomatic Carotid Stenosis Glenn Jacobowitz, MD
DEBATE: We Should Stop Screening For Asymptomatic Carotid Stenosis Even Though There Is A Substantial Incidence Of Silent Cerebral Events In These Patients: What Should We Do About It

Alan H. Davies, MA, DM

What’s New About The Role Of Cilostazol In Patients With Vascular Disease: What Are Some Of Its Newly Found Benefits

Anthony J. Comerota, MD

DEBATE: Should Vascular Patients Be Taking A Polypill (Or Multiple Pills) For Secondary Prophylaxis: Yes, It Decreases Risk And Is Cost Effective

Don Poldermans, MD

DEBATE: Should Vascular Patients Be Taking A Polypill (Or Multiple Pills) For Secondary Prophylaxis: No, It Is Too Dangerous; Better To Wait For Symptoms

Erich Minar, MD

Panel Discussion

Lunch Break – Americas Hall 1, 3rd Floor
Visit Exhibits and Pavilions (2nd and 3rd Floors)
What Percent Of Diabetics With CLI Can Undergo Revascularization: With PTA: With Bypass
Giacomo Clerici, MD

Use Of OCT (Optical Coherent Tomography) For Crossing Chronic Total Occlusions
Tony S. Das, MD

Panel Discussion

Moderators: Roger M. Greenhalgh, MD
Ali F. AbuRahma, MD

Aortic Topics

A New One-Shot Aortic Occlusion Balloon
Benjamin W. Starnes, MD

3D Imaging And Robotic Catheter Navigation: How Can They Work Together To Facilitate Complex Aortic Procedures
Alan B. Lumsden, MD

DEBATE: The Long-Term Results Of Open Repair Are Better Than Those Of EVAR In Most Patients
Wilhelm Sandmann, MD

DEBATE: The Long-Term Results Of EVAR Are Better Than Those Of Open Repair: The EVAR I Late Results Have Been Misinterpreted In The NEJM Article
Juan C. Parodi, MD

EVAR I Results Are Not In Accord With Contemporary Practice Results: EVAR Is Better Than Open Repair With Superior Outcomes
Ian Loftus, MD
Matt M. Thompson, MD

DEBATE: IFUs For EVAR Should Not Be Stretched: The Results Don't Justify It
Andres Schanzer, MD

DEBATE: A Propensity Matched Comparison Of EVAR And Open Repair Shows That EVAR Is Superior Even When IFUs Are Stretched Because Of Imperfect Anatomy
William D. Jordan, Jr., MD

DEBATE: Bare Stents Are The Best Treatment For Most Adult Aortic Coarctations: Why Is This So
Christoph A. Nienaber, MD, PhD

DEBATE: Covered Stents Are The Best Treatment For Most Adult Aortic Coarctations
Dietmar H. Koschyk, MD

Update On Use Of Atrium Advanta V12 Balloon Expandable Stent-Grafts For Treatment Of Aortic Coarctation: Advantages, Limitations And Precautions: From The OUS Trial
Elchanan Bruckheimer, MBBS

Are Fenestrated And Branched Endografts A Better Option For Treating Chronic Type B Aortic Dissections And Associated Aneurysms
Stephan Haulon, MD

Panel Discussion

Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)
SESSION 31 (Grand Ballroom West, 3rd Floor)
PROGRESS IN THE TREATMENT OF VENOUS DISEASE – PART IA (5-MINUTE TALKS)
Moderators: Mark H. Meissner, MD
Lowell S. Kabnick, MD

9:25 – 9:30  Current Treatment For Giant A-V Fistulas Of Renal And Visceral Vessels: Is Endovascular Treatment Feasible And How
Peter Gloriczki, MD

9:31 – 9:36  Current Optimal Surgical Treatment Of Phlegmasia Cerulea Dolens
Kampkol Laohapensang, MD

9:37 – 9:42  Incidence Of Upper Extremity DVT After Central Venous Catheter Placement: Implications And What To Do About It
Gregory L. Moneta, MD

9:43 – 9:48  Superior Vena Cava Aneurysm: Natural History And Indications For Treatment
J. Leonel Villavicencio, MD

9:49 – 9:54  Venous Aneurysms: What Are They And Are They Dangerous: Rupture Risk Has Been Exaggerated And Not All Need To Be Repaired
Jerry Goldstone, MD

9:55 – 10:00  Tips And Tricks For Iliac Vein And IVC Stenting: Access, Crossing Lesions, Stent Choice And Size
Ramesh K. Tripathi, MD

10:01 – 10:06  Current Status Of Stenting For Iliac Vein And Caval Disease: Indications, Which Stent Is Best, Precautions
Seshadri Raju, MD
Peter Neglen, MD, PhD

10:07 – 10:12  Iliac Vein Stenting For Advanced Chronic Venous Disease: When Will It Improve Symptoms And When Will It Not: Is IVUS Essential
Anil P. Hingorani, MD
Enrico Ascher, MD

10:13 – 10:18  Connecticut Experience With Wall Stenting For Iliac Vein Disease Under IVUS Control: Raju And Neglen Are Right
Paul J. Gagne, MD

10:19 – 10:24  Is There Any Treatment Available For Patients Who Already Have Postthrombotic Syndrome?
Jose I. Almeida, MD, RVT

10:25 – 10:35  Panel Discussion

SESSION 32 (Grand Ballroom West, 3rd Floor)
PROGRESS IN THE TREATMENT OF VENOUS DISEASE – PART 1B (5-MINUTE TALKS)
Moderators: Bo G. Eklof, MD, PhD
Jose I. Almeida, MD, RVT

10:35 – 10:40  Current Optimal Management Of Paget-Schroetter’s Syndrome
George H. Meier III, MD

10:41 – 10:46  Upper Extremity DVT: Early Lysis And Rib Resection Improves Outcomes
Ian Loftus, MD

10:47 – 10:52  1-Stage Aggressive Treatment Of Paget-Schroetter Syndrome: What Does It Involve And Why Is It Best
Karl A. Ililig, MD
SESSION 33 (Grand Ballroom East, 3rd Floor)
MORE ON TEVAR, TAAAs AND PARARENAL ANEURYSMS, THEIR TREATMENT AND THE MULTILAYER STENT (5-MINUTE TALKS)

Moderators: Ronald M. Fairman, MD
Mark A. Adelman, MD

1:00 – 1:05
Fenestrated And Branched Grafts To Repair Visceral Patch Aneurysms After Open TAAA Repair
James H. Black III, MD

1:06 – 1:11
Risk Stratification And Prediction Of Long-Term Success After TEVAR For Thoracic Aneurysm Based On The MOTHER Registry
Ian Loftus, MD
Matt M. Thompson, MD

Topics Related To The Multilayer Flow Modulating Stent

1:12 – 1:17
Value Of The Cardiatis Multilayer Flow Modulating Stent For The Treatment Of Non-Aortic Aneurysms
Antonella Ruffino, MD
Claudio Rabbia, MD, PhD

1:18 – 1:23
Does The Multilayer Stent Exclude And Fix Aortic Aneurysms: Summary Of The French Experience
Claude D. Vaislic, MD

1:24 – 1:29
Results Of Treatment Of Complex TAAAs With The Multilayer Uncovered Stent: The Moroccan Experience
Amira Benjelloun, MD

1:30 – 1:35
With TAAAs, Does The Multilayer Stent Promote Aneurysm Sac Shrinkage And Prevent Rupture: What Is The Evidence
Sherif Sultan, MD
Niamh Hynes, MD

1:36 – 1:41
Chinese Experience With The Multilayer Stent For Treatment Of Complex Aortic Aneurysms
Qingsheng Lu, MD
Zaiping Jing, MD

1:42 – 1:47
Is The Multilayer Stent An Effective Treatment For Arch Aneurysms And TAAAs: What Happens To Sac Pressure And Aneurysm Size After Treatment: Is Rupture Prevented
Thomas Larzon, MD

1:48 – 1:53
DEBATE: The Multilayer Stent Is Going To Work For The Treatment Of Complex Aortic Aneurysms: Theoretical Considerations And Clinical Experience
Edward B. Diethrich, MD

1:54 – 1:59
DEBATE: The Multilayer Stent Is Not Going To Work For The Treatment Of Complex Aneurysms: Theoretical Considerations
Luigi Inglese, MD

2:00 – 2:05
Another Skeptical View On The Value Of The Multilayer Stent For The Treatment Of Complex Aortic Aneurysms
Piergiorgio Cao, MD

2:06 – 2:12
Panel Discussion
SESSION 34 (Grand Ballroom East, 3rd Floor)

PROGRESS IN VASCULAR IMAGING AND GUIDANCE (5-MINUTE TALKS)

Moderators: Brian R. Hopkinson, ChM
John H. Furtek, BS, RT(r)

2:12 – 2:17 Can Ninnvasive Imaging Keep Up With Evolving Technology
Allan W. Reid, FRCR

2:18 – 2:23 All The Things You Can Learn From Transcranial Doppler (TCD) That Most Of Us Don’t Know About: A New Look At TCD
Zsolt Garami, MD

2:24 – 2:29 The Value Of Hansen Magellen Robotic Assisted Catheter Manipulation For Complex Aortic Endografting
Nicholas J.W. Cheshire, MD

2:30 – 2:35 Little Known Tips And Tricks For Making CO₂ Angiography Work Better Than Commonly Thought
Kyung Cho, MD

Barry T. Katzen, MD

2:42 – 2:47 IVUS Guided EVAR And TEVAR Is Feasible And Effective: Tips And Tricks
Martin R. Back, MD

2:48 – 2:53 Vascular Imaging Strategies For Patients With Renal Insufficiency Requiring MR Imaging
Barry Stein, MD

2:54 – 2:59 Noninvasive Quantification Of Pressure Gradients And Flow With 4D Flow Sensitive MRI: What Unique Information Can This Technique Tell Us In Aortic Dissection
Jon S. Matsusmura, MD
Chris Francois, FRCS

3:00 – 3:05 Encouraging 1-Year Clinical Results With A Spiral Flow Prosthetic Graft In Lower Extremity Bypasses
Nick Shaper, FRCS

3:06 – 3:30 Panel Discussion And Break
Visit Exhibits and Pavilions (2nd and 3rd Floors)

PROGRAM H (SESSIONS 35 – 36)
(Grand Ballroom West, 3rd Floor)

SESSION 35 (Grand Ballroom West, 3rd Floor)
MORE NEW CONCEPTS ABOUT AAAs, EVAR AND OTHER TREATMENTS OF AORTIC DISEASE (5-MINUTE TALKS)

Moderators: Timur P. Sarac, MD
Palma M. Shaw, MD

1:00 – 1:05 Fenestrated Cuff-Extender For Treatment Of Migrated Infrarenal Endografts: Midterm Results
Krassi Ivancev, MD, PhD

1:06 – 1:11 Do Most AAA Patients Survive Long Enough To Benefit From Aneurysm Repair
Jack L. Cronenwett, MD

1:12 – 1:17 New Findings Regarding Treatment Of Infection Following AAA Repair By EVAR Or Open Surgery
Laura Capocci, MD, PhD
Strategies To Minimize Blood Loss During EVAR Procedures And Why It Is Important
Claude Mialhe, MD

Off-The-Shelf Device For Pararenal Aneurysms
Mark A. Farber, MD

How To Place Bifurcated Devices In Patients With Iliac Occlusions
David J. Minion, MD
Mark A. Farber, MD
William D. Jordan, Jr., MD

When Should Thoracic Endografts Be Ballooned: How Can Ballooning Be Harmful
Jean Bismuth, MD

Endovascular Treatment Of Various Pathologic Lesions Involving The Aortic Arch
Dittmar Boeckler, MD

Endovascular Treatment Of Aortic Arch Lesions: What Device Can Be Used To Treat Which Lesions
Nicola Mangiardi, MD

Use Of Motor Evoked Potential And Leaving A Side Branch Open With Delayed Closure To Prevent Spinal Cord Ischemia During Endovascular TAAA Repair
Geert W.H. Schurink, MD, PhD
Michael J. Jacobs, MD

Experience With Endostapling (Aptus HeliFX) For Endograft Fixation: It Really Works With Short Necks
Burkhart Zipfel, MD

Intrasac Flow Characteristics Of An Enlarging AAA With A Type II Endoleak After EVAR: What To Do To Fix It
Julio A. Rodriguez-Lopez, MD

How To Eliminate Gutter Leakage After Chimney And Periscope Grafts: Based On An In Vitro Measurement Study
Jan D. Blankensteijn, MD

Endograft Type And Sizing For Successful Parallel Endografts Or CHIMPS
David J. Minion, MD

I Have Been Converted: For Some TAAAs Open Surgery Should Be Replaced By Endovascular Treatments: When Should It Not Be
Joseph S. Coselli, MD

Is There A Difference In Outcome Between Double And Triple Or Quadruple Fenestrated Grafts: Findings Of The GLOBALSTAR Registry
Peter L. Harris, MD
S. Rao Vallabh Huneni, MD

CHIMPS: How And When Do They Work And When Don’t They
Ralf R. Kolvenbach, MD
DEBATE: CHIMPS Will Have A Major Role Even When Fenestrated And Branched Grafts Are Widely Available
Frank J. Criado, MD

DEBATE: The Current State-Of-The-Art In Fenestrated And Branched Endografts: When Widely Available They Will And Should Eliminate The Need For CHIMPS
Roy K. Greenberg, MD
Tara M. Mastracci, MD

What Can Be Expected From Chimney Grafts In Para And Juxtarenal AAAs: Are They As Good As Some Say
Jean-Pierre Becquemin, MD

Tips And Tricks To Make Chimney Grafts Work For Juxta And Pararenal AAAs
Alan M. Graham, MD

A Simple Technique Of Limb Perfusion To Prevent Limb Ischemia From Complex Lengthy EVARs
Timothy A. Resch, MD, PhD

Panel Discussion And Break
Visit Exhibits and Pavilions (2nd and 3rd Floors)

PROGRAM I (SESSIONS 37 – 38: ARTERIAL)
(Grand Ballroom East, 3rd Floor)
SESSION 37
(Grand Ballroom East, 3rd Floor)
UPDATES, CONTROVERSIES AND NEW CONCEPTS IN THE TREATMENT OF RUPTURED AAAs
(5-MINUTES TALKS)
Moderators: Nicholas J.W. Cheshire, MD
Frank J. Veith, MD

Update On Dutch Ruptured AAA RCT Of EVAR vs. Open Repair
Willem Wisselink, MD

DEBATE: We Still Need Level I Evidence To Support Use Of EVAR With Ruptured AAAs: Update On The Findings Of The UK IMPROVE Trial
Janet T. Powell, MD, PhD

DEBATE: We Don’t Need A RCT: All Ruptured AAAs Can Be Treated Endovascularly And The Results Are Excellent
Dieter O. Mayer, MD
Thomas Larzon, MD

EVAR Must Be Part Of Any Ruptured AAA Program: Based On A Consensus Panel Finding
Marc R.H.M. van Sambeek, MD, PhD

Why Open Repair Is Still The Gold Standard For Treatment Of Ruptured AAA
Jürg Schmidli, MD

DEBATE: With Ruptured AAAs The Turn-Down Rate For Treatment Is Key
Ian Loftus, MD
Matt M. Thompson, MD

DEBATE: Technique Not Turn-Down Rate Is Important: Tips And Tricks To Get Good Outcomes From EVAR For AAAs Short-Term And Long-Term
Mario Lachat, MD
Dieter O. Mayer, MD
Frank J. Veith, MD
Are Outcomes Of Treatment For Ruptured AAAs Better If A Specialist Vascular Surgeon Is Caring For The Patient Than Some Other Specialist (General Surgeon Or Cardiac Surgeon)

Florian Dick, MD

Prophylactic Use Of Polypropylene Mesh Overlay In Open Repair For AAAs Decreases The 30% Incisional Hernia Rate

Sebastian E. Debus, MD, PhD

Is The Transfer Of RAAA Patients To Specialized Centers From Smaller Hospitals Worthwhile: A UK Delphi Consensus Study Shows It Is Under Certain Conditions

Robert J. Hinchliffe, MD


Jesper Swedenborg, MD, PhD

Degree Of Calcification As A Prognostic Factor For Rupture With AAAs

Clark J. Zeebregts, MD, PhD

ENDOVASCULAR TREATMENT OF TRAUMATIC AORTIC TRANSECTION IN YOUNG PATIENTS: PROBLEMS ENCOUNTERED AND HOW TO SOLVE THEM

Giorgio M. Biasi, MD

Impact Of Proper Device Sizing In Traumatic Aortic Injuries: How Should Graft Size Be Determined

Mark A. Farber, MD

10-Year Follow-up Of TEVAR For Traumatic Aortic Transection: How Durable Is The Procedure And The Endograft

Karl H. Orend, MD

What Happens After TEVAR For Traumatic Aortic Transection

Mark Conrad, MD
Richard P. Cambria, MD

A New More Accurate Method For Measuring False Lumen Thrombosis (FLTx) In Type B Aortic Dissections: 3D MRI With Blood Pool Contrast Agent Obviates Overestimation Of FLTx

Rachel Clough, MD, PhD
Peter R. Taylor, MA, MChir

Computational Flow Analysis In Type B Aortic Dissections: Lessons Learned

Zhuo Cheng, PhD

Volumetric Assessment Of Type B Aortic Dissections On CT Imaging: Can We Predict Which Patients Will Have False Lumen Thrombosis

Frank R. Arko, MD
DEBATE: Fenestrated And Branched Endograft Solutions Are Better Than A Petticoat Graft (Proximal Covered Stent And Distal Bare Stent) For Complicated Type B Aortic Dissections
Eric L.G. Verhoeven, MD, PhD

DEBATE: Fenestrated And Branched Endografts Are Not Better Than A Petticoat Graft For Complicated Type B Dissections – Even If Chronic
Germano Melissano, MD
Roberto Chiesa, MD

Update From The STABLE Trial: The Petticoat Concept Of A Proximal Covered Stent And A Distal Bare Stent Is Supported By Follow-up To 2 Years: When Is The Distal Bare Stent Indicated
Joseph V. Lombardi, MD

Panel Discussion

PROGRAM J (SESSIONS 39 – 40: VENOUS)
(GRAND BALLROOM WEST, 3RD FLOOR)

SESSION 39 (Grand Ballroom West, 3rd Floor)
MORE PROGRESS IN THE TREATMENT OF VENOUS DISEASE - PART IIA (5-MINUTE TALKS)
Moderators: Joann Lohr, MD
J. Leonel Villavicencio, MD

3:30 – 3:35
Neurological Complications Of Sclerotherapy For Varicose Veins: Incidence And Prevention
Alun H. Davies, MA, DM

3:36 – 3:41
Radiofrequency Treatment Of Perforating Veins For Recalcitrant Venous Ulcers: How To Do It And Does It Help
Peter F. Lawrence, MD

3:42 – 3:47
Local Hyperbaric O2 To Heal Refractory Venous Ulcers
Sherif Sultan, MD
Niamh Hynes, MD

3:48 – 3:53
Update And Clinical Experience With Biodegradable IVC Filter
David Rosenthal, MD

3:54 – 3:59
Why Routine IVC Filters Should Be Placed In Patients With Massive And Submassive PEs
Gary M. Ansel, MD

4:00 – 4:05
Novel Technique For Removing Retrievable IVC Filter When Its Hook Cannot Be Snared
Benjamin M. Jackson, MD
Ronald M. Fairman, MD

4:06 – 4:11
Non-Lipid Lowering Effects Of Crestor On DVT
Thomas W. Wakefield, MD

4:12 – 4:17
Improved Bioprosthetic Valve For Treatment Of Deep Venous Insufficiency: Value Of Autologous Endothelial Cells
Dusan Pavcnik, MD, PhD

4:18 – 4:23
Superficial Vein Thrombophlebitis: To Treat Or Not To Treat
Joseph D. Raffetto, MD

4:24 – 4:29
How To Decrease The Risk Of Anastomotic Stenosis And Occlusion In Bypasses For Takayasu’s Disease
Byung-Boong Lee, MD

4:30 – 4:40
Panel Discussion
SESSION 40 (Grand Ballroom West, 3rd Floor)
PROGRESS IN ENDOVASCULAR TREATMENT OF MASSIVE AND SUBMASSIVE PULMONARY EMBOLI AND OTHER HOT VENOUS TOPICS – PART IIB (5-MINUTE TALKS)

Moderators: Bo G. Eklof, MD, PhD
Nicholas J. Morrissey, MD

4:40 – 4:45
Ultrasound-Assisted Thrombolysis For Massive And Submassive PE
Nils Kucher, MD
Iris Baumgartner, MD

4:46 – 4:51
New Findings In The Use Of Ultrasound Accelerated Thrombolysis In The Treatment Of Submassive PEs
Tod E. Engelhardt, MD

4:52 – 4:57
Endovascular Treatment Of Massive PE: How And When Should It Be Done
David L. Gillespie, MD

4:58 – 5:03
Update On VORTEX Suction Thrombectomy Catheter To Treat PEs And IVC Thrombi: Clinical Experience, Safety And Precautions
Christopher J. Kwolek, MD

5:04 – 5:09
Does Treatment With The Trellis Mechanical Thrombectomy Device Decrease The Postthrombotic Syndrome After 2 Years: Results Of The ISOL-8 Multicenter Trial
Paul J. Gagne, MD

5:10 – 5:15
Value Of Ultrasound Accelerated Thrombolysis In DVT: When Is It Indicated
Cees H.A. Wittens, MD, PhD

5:16 – 5:21
Update On New Anticoagulants For Venous Thromboembolism Prophylaxis And Treatment
Thomas W. Wakefield, MD

5:22 – 5:27
Should Venous IVUS Be Used In All Serious Leg Swelling Patients To Detect Lymphedema From Venous Disease So It Can Be Treated By Stenting
Seshadri Raju, MD

5:28 – 5:33
New Technique For Deep Venous Valve Reconstruction
Ramesh K. Tripathi, MD

5:34 – 5:39
The Relationship Between Venous And Arterial Disease: Is Venous Disease Really An Arterial Problem
Seshadri Raju, MD

5:40 – 5:45
How Should We Manage The Unretrievable Retrievable IVC Filter
Werner Lang, MD

5:46 – 6:00
Panel Discussion
SESSION 41 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN AAAs AND THEIR TREATMENT (5-MINUTE TALKS)

Moderators: K. Wayne Johnston, MD
Dhiraj M. Shah, MD

6:40 – 6:45 Impact Of A Redeployable AAA Stent-Graft (Gore Excluder C-3) To Improve Proximal Seal In Difficult Anatomy: Does It Make A Difference
Eric L.G. Verhoeven, MD, PhD

6:46 – 6:51 Is A Thick Layer Of Neck Thrombus A Contraindication For EVAR
Hence J.M. Verhagen, MD, PhD

6:52 – 6:57 Final Result Of The PEVAR Trial: A RCT Comparing Percutaneous With Open Access For EVAR
Zvonimir Krajer, MD

6:58 – 7:03 Open And Endovascular Repair Of Para-Anastomotic Aneurysms
Geriano Melissano, MD
Roberto Chiesa, MD

7:04 – 7:09 Transecting The Left Renal Vein For Aortic Surgery: Why, How, When And Why Not
Afshin Assadian, MD

7:10 – 7:15 DEBATE: Laparoscopic Vascular Surgery Should Be Growing And Vascular Surgeons Should Learn It And Do It
Joseph S. Giglia, MD

7:16 – 7:21 DEBATE: Why Laparoscopic And Robotic Aortic Surgery Are Losing Their Appeal And Will Not Become Widespread
Willems Wisselink, MD

7:22 – 7:27 The Rise And Fall Of AAAs: The Decreasing Incidence Of AAAs: What Is The Cause
Frank A. Lederle, MD

7:28 – 7:33 Is EVAR Indicated And Justified For Inflammatory AAAs: When Is It Not
Samuel R. Money, MD, MBA

7:34 – 7:39 Is There A Role For AUI Endografts For EVAR
In 2012: Should One Be In Your Endovascular Tool Box For Emergency Use
Thomas L. Forbes, MD

7:40 – 7:45 Feasibility Of EVAR For Infected AAAs: When Does It Work And When Doesn’t It
Chung-Dann Kan, MD, PhD

7:46 – 7:51 How To Manage Infected Aortic Endografts
Edward Y. Woo, MD
Ronald M. Fairman, MD

7:52 – 7:57 Long-Term Quality Of Life Data After EVAR And Open Repair: From The DREAM Trial: Open Repair Wins And Why
Jan D. Blankensteijn, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:58</td>
<td>The Vital Focus On EVAR vs. Open Repair At 15 Years: Is The Game Changing</td>
<td>Roger M. Greenhalgh, MD</td>
</tr>
<tr>
<td>8:04</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>8:13</td>
<td>How Does Transcatheter Intra-arterial Denervation Work: Who Should Be Treated And Who Should Not: Why Is the Artery Not Injured And Are There Dangers From The Treatment</td>
<td>Dieter Scheinert, MD</td>
</tr>
<tr>
<td>8:19</td>
<td>What Are The Secondary Benefits – Other Than Reducing Blood Pressure – To Renal Denervation: When Will This Treatment Be Available In The US And How Long Will All Benefits Last</td>
<td>Michael R. Jaff, DO, Ido Weinberg, MD, MSc</td>
</tr>
<tr>
<td>8:25</td>
<td>Status Of Renal PTA And Stenting After ASTRAL And CORAL: What’s New In The Field</td>
<td>Thomas A. Sos, MD</td>
</tr>
<tr>
<td>8:37</td>
<td>Long-Term Outcomes Of PTA And/or Stenting For Renal Fibromuscular Hyperplasia: What Is The Best Treatment</td>
<td>Albeir Y. Mousa, MD, Ali F. AbuRahma, MD</td>
</tr>
<tr>
<td>8:43</td>
<td>Best Method To Assess SMA Stents: How Does Duplex Correlate With Pressure Measurements, CTA And Clinical Outcomes</td>
<td>Timothy A. Resch, MD, PhD</td>
</tr>
<tr>
<td>8:49</td>
<td>Early And Late Outcomes Of PTA And Stenting Of Celiac And SMA Occlusive Disease: Advantages, Limitations And Results Up To 10 Years</td>
<td>Ali F. AbuRahma, MD</td>
</tr>
<tr>
<td>8:55</td>
<td>Can The Results Of Mesenteric Revascularization Improve With Covered Stents And Distal Protection Devices</td>
<td>Gustavo S. Oderich, MD</td>
</tr>
<tr>
<td>9:01</td>
<td>How To Treat Isolated SMA Dissections: When Medical vs. Interventional vs. Surgical Therapy</td>
<td>Young Wook Kim, MD</td>
</tr>
<tr>
<td>9:07</td>
<td>Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**NEW DEVELOPMENTS IN TREATMENT OF THE AORTA AND ITS BRANCHES (5-MINUTE TALKS)**

**Moderators:** Ross Milner, MD, Jean-Pierre Becquemin, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:18</td>
<td>What Are The Secondary Benefits – Other Than Reducing Blood Pressure – To Renal Denervation: When Will This Treatment Be Available In The US And How Long Will All Benefits Last</td>
<td>Michael R. Jaff, DO, Ido Weinberg, MD, MSc</td>
</tr>
<tr>
<td>8:24</td>
<td>Status Of Renal PTA And Stenting After ASTRAL And CORAL: What’s New In The Field</td>
<td>Thomas A. Sos, MD</td>
</tr>
<tr>
<td>8:30</td>
<td>Frontiers In Renal Artery Stenting: What Does The Future Hold: Better Stents, Better Balloons, Etc.</td>
<td>Max Amor, MD</td>
</tr>
<tr>
<td>8:36</td>
<td>Long-Term Outcomes Of PTA And/or Stenting For Renal Fibromuscular Hyperplasia: What Is The Best Treatment</td>
<td>Albeir Y. Mousa, MD, Ali F. AbuRahma, MD</td>
</tr>
<tr>
<td>8:41</td>
<td>Best Method To Assess SMA Stents: How Does Duplex Correlate With Pressure Measurements, CTA And Clinical Outcomes</td>
<td>Timothy A. Resch, MD, PhD</td>
</tr>
<tr>
<td>8:47</td>
<td>Early And Late Outcomes Of PTA And Stenting Of Celiac And SMA Occlusive Disease: Advantages, Limitations And Results Up To 10 Years</td>
<td>Ali F. AbuRahma, MD</td>
</tr>
<tr>
<td>8:52</td>
<td>Can The Results Of Mesenteric Revascularization Improve With Covered Stents And Distal Protection Devices</td>
<td>Gustavo S. Oderich, MD</td>
</tr>
<tr>
<td>9:03</td>
<td>How To Treat Isolated SMA Dissections: When Medical vs. Interventional vs. Surgical Therapy</td>
<td>Young Wook Kim, MD</td>
</tr>
<tr>
<td>9:09</td>
<td>Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**SESSION 42 (Grand Ballroom East, 3rd Floor)**

**Moderators:** Michael B. Silva, Jr., MD, James C. Stanley, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:19</td>
<td>DEBATE: Treatment Of Mid-Aortic Syndrome In Young Adults: Interventional Treatment Is Indicated In Some</td>
<td>Ramesh K. Tripathi, MD</td>
</tr>
<tr>
<td>9:25</td>
<td>DEBATE: Interventional Therapy Is Never Indicated For Mid-Aortic Syndrome At Any Age: Open Surgery Is Best</td>
<td>Wilhelm Sandmann, MD</td>
</tr>
</tbody>
</table>
SESSIONS 42–43

FRIDAY
SESSION 42 (Grand Ballroom East, 2nd Floor)
FUTURE ISSUES REGARDING HEALTH CARE; CONFLICT OF INTEREST; GOVERNMENT; INDUSTRY RELATIONS; BUSINESS OF MEDICINE; PRACTICE COSTS; AND REIMBURSEMENTS (5-MINUTE TALKS)
Moderators: Julius H. Jacobson II, MD
Kenneth Ouriel, MD, MBA

10:20 – 10:25 How To Succeed With A Physician Founded Medical Device Company: The Embrella Device As An Example
Jeffrey P. Carpenter, MD

10:26 – 10:31 Physician Focused Tort Reform By Limiting Expert MD Testimony Fees And Taking Other Accountability Measures: We Physicians Can Stop Medical Malpractice Abuses No Matter What The Damned Lawyers Do
O. William Brown, MD, JD

10:32 – 10:37 What Will Health Care Reform Mean To Practicing Vascular Surgeons, Hospitals And Surgical Services
Robert M. Zwolak, MD, PhD

10:38 – 10:43 What's Happening With Vascular Reimbursement
Sean P. Roddy, MD

Michael C. Stoner, MD

10:50 – 10:55 Disclosure And Conflict Of Interest: Have We Gone Too Far Or Not Far Enough
Timothy M. Sullivan, MD

Barry T. Katzen, MD

11:02 – 11:07 Physician-Industry Relationships And Conflict Of Interest: No Conflict – No Interest – No Success: How To Deal With The Pitfalls And Problems – Legally And Ethically
Scott L. Stevens, MD

SESSIONS 42–43

SATURDAY
SESSION 43 (Grand Ballroom East, 3rd Floor)
FUTURE ISSUES REGARDING HEALTH CARE; CONFLICT OF INTEREST; GOVERNMENT; INDUSTRY RELATIONS; BUSINESS OF MEDICINE; PRACTICE COSTS; AND REIMBURSEMENTS (5-MINUTE TALKS)
Moderators: Julius H. Jacobson II, MD
Kenneth Ouriel, MD, MBA

10:20 – 10:25 How To Succeed With A Physician Founded Medical Device Company: The Embrella Device As An Example
Jeffrey P. Carpenter, MD

10:26 – 10:31 Physician Focused Tort Reform By Limiting Expert MD Testimony Fees And Taking Other Accountability Measures: We Physicians Can Stop Medical Malpractice Abuses No Matter What The Damned Lawyers Do
O. William Brown, MD, JD

10:32 – 10:37 What Will Health Care Reform Mean To Practicing Vascular Surgeons, Hospitals And Surgical Services
Robert M. Zwolak, MD, PhD

10:38 – 10:43 What's Happening With Vascular Reimbursement
Sean P. Roddy, MD

Michael C. Stoner, MD

10:50 – 10:55 Disclosure And Conflict Of Interest: Have We Gone Too Far Or Not Far Enough
Timothy M. Sullivan, MD

Barry T. Katzen, MD

11:02 – 11:07 Physician-Industry Relationships And Conflict Of Interest: No Conflict – No Interest – No Success: How To Deal With The Pitfalls And Problems – Legally And Ethically
Scott L. Stevens, MD
SESSION 44 (Grand Ballroom East, 3rd Floor)
TRIBUTE TO OUR MILITARY (5-MINUTE TALKS)
Moderators: Norman M. Rich, MD
Todd E. Rasmussen, MD

11:43 – 11:48
From The Front Lines To The Ivory Tower And Back: How Advances At Walter Reed National Military Medical Center Are Used At The Front
Robert Craig, DO

11:48 – 11:54
A Brief History Of The Tourniquet In Battle
Norman M. Rich, MD

11:55 – 12:00
Vascular Surgery Lessons Learned After A Decade Of War In Iraq And Afghanistan
Todd E. Rasmussen, MD

SESSION 45 (Grand Ballroom East, 3rd Floor)
LUNCHEON SESSION: NEW OR IMPROVED ENDOVASCULAR DEVICES (5-MINUTE TALKS)
Moderators: Eric L.G. Verhoeven, MD, PhD
Juan C. Parodi, MD

12:01 – 12:06
Recent Improvements In The Cook Zenith AAA Endograft: How Do They Make A Difference
Tara M. Mastroacci, MD

12:07 – 12:12
Update On Advantages And Limitations Of The Lombard AORFIX Graft: When Will It Be Approved In The US
Brian R. Hopkinson, ChM
Mark F. Fillinger, MD

12:13 – 12:18
Worldwide Experience With The Aptus HELIFX Endostaples: Can They Fix Endoleaks And Prevent Aortic Neck Enlargement And Migration
David H. Deaton, MD

12:19 – 12:24
Update On The NELLIX Device For EVAR: Advantages And Limitations
Jeffrey P. Carpenter, MD

12:25 – 12:30
Off-The-Shelf Fenestrated VENTANA Device For Renal Revascularization With Juxta And Pararenal AAAs: Clinical Update And Will In Situ Fenestration Be Possible With Newer Multilayer Stretchable PTFE Endograft Coverings
Daniel G. Clair, MD
Advantages And Limitations Of The INCRAFT From Cordis: 1-Year Clinical Data From The INNOVATION Trial
Dierk Scheinert, MD

Description And Clinical Experience With The Anaconda Fenestrated Endograft For Juxta And Pararenal AAAs
Clark J. Zeebregts, MD, PhD

Worldwide Mid-Term Results (2-Year) Of The Endurat Endograft For AAAs: Does It Expand The Proportion Of Patients Who Can Undergo EVAR Safely And Effectively
Dittmar Boeckler, MD
Michel S. Makaroun, MD

Current Status Of The Bolton TREOVANCE AAA Endograft: Advantages And Limitations
Edward Y. Woo, MD
Ronald M. Fairman, MD

Panel Discussion

SESSION 46 (Grand Ballroom East, 3rd Floor)
ISSUES RELATED TO TRAINING, CERTIFICATION, SIMULATION, SPECIALTIES, GUIDELINES AND RANDOMIZED CONTROLLED TRIALS (5-MINUTE TALKS)
Moderators: Mario Lachat, MD
Karl A. Illig, MD

What’s New With Maintenance Of Certification (MOC) Requirements For Vascular Surgeons
Anton N. Sidawy, MD, MPH

Recent Developments In The Evolution Of Vascular Training And Training Programs: Current Status Of The 0:5 Programs And Number Of Vascular Surgery Applicants And Spots
Karl A. Illig, MD

How To Redesign Workflow To Improve Patient Care And Resident Training
Richard J. Powell, MD

Advantages Of Case Specific Simulator Rehearsal With Endovascular Procedures
Isabelle Van Herzeele, MD, PhD

What’s New And Better With The Pontresina Vascular Surgery Simulator Course For Trainees
Hans-Henning Eckstein, MD, PhD

Guidelines Are Outdated By The Time They Are Published: Some Examples
Janet T. Powell, MD, PhD

Randomized Controlled Trials Can Be Misleading Even When Reported In Leading Journals: Guidelines Based On These Trials Can Also Be Misleading
Frank J. Veith, MD

Advantages And Limitations Of The OVATION Endograft (TriVascular) For AAA Repair: Based On The 1-Year Global Experience
Manish Mehta, MD, MPH

Cost Effectiveness Of Different Treatment Strategies For CLI With Gangrene Or Necrosis
Michael Belkin, MD

Panel Discussion
SESSION 47 (Grand Ballroom East, 3rd Floor)
MORE ABOUT HEALTH CARE REFORM, FDA, ETHICS, COSTS, STANDARDS AND GUIDELINES (5-MINUTE TALKS)

Moderators: Kim J. Hodgson, MD
Thomas F. O’Donnell, Jr., MD

2:00 – 2:05
Impact Of Obamacare On Medicine In The US
Clifford J. Buckley, MD
Shirley Buckley, RN

2:06 – 2:11
Why The Canadian Health Care System Works Better Than Obamacare Will
Dheeraj Rajan, MD

2:12 – 2:17
How Should Aviation Training Serve As A Model For Educating Vascular Surgeons
John F. Eidt, MD

2:18 – 2:23
What Has And Will The FDA Do To Medical Innovation In The US: An FDA Consultant’s Perspective: Will Things Improve
Thomas J. Fogarty, MD

2:24 – 2:29
Dorothy B. Abel, BS, BME
Kenneth J. Cavanaugh, Jr., PhD

2:30 – 2:35
How To Get A Physician-Sponsored IDE: Tips And Tricks
Benjamin W. Starnes, MD

2:36 – 2:41
Advantages Of The ESVS (European Society for Vascular Surgery) Guidelines For Vascular Surgery: Some Examples As To Why They Are Better Than US Guidelines
Jean-Baptiste Ricco, MD, PhD

2:42 – 2:47
Current State Of The SVS Vascular Quality Initiative: Is It Growing And Is It Working
Jack L. Cronenwett, MD

2:48 – 2:53
Vascular Quality Initiatives: A Dark Cloud Behind A Silver Lining: What Are Some Of The Problems And How Can They Be Resolved
Scott L. Stevens, MD

2:54 – 3:10
Panel Discussion And Break
Visit Pavilions and Exhibits (2nd and 3rd Floors)

CONCURRENT SATURDAY AFTERNOON PROGRAMS

PROGRAM K (SESSIONS 48 – 49)
3:10 P.M. – 6:10 P.M.
Vascular Disease; Medical Treatment; Complications, New Techniques And Concepts
Grand Ballroom East, 3rd Floor

PROGRAM L (SESSIONS 50 – 51)
3:10 P.M. – 6:10 P.M.
Updates, New Technology And Concepts; More New Concepts, Updates And Techniques
Grand Ballroom West, 3rd Floor
SESSION 48 (Grand Ballroom East, 3rd Floor)

VASCULAR DISEASE NATURAL HISTORY; MEDICAL TREATMENT; PREVENTION AND TREATMENT OF COMPLICATIONS (5-MINUTE TALKS)

Moderators: Vivian Gahtan, MD
Peter F. Lawrence, MD

3:10 – 3:15  New Developments In Anticoagulant Drugs For Vascular Patients
Anthony J. Comerota, MD

3:16 – 3:21  Decision Making Tool For Determining Which CLI Treatment Is Best: Open vs. Endovascular
Darren B. Schneider, MD

3:22 – 3:27  Ongoing Developments In Drug Treatment Of Vascular Disease: Do HDL Raising Drugs Show Promise For Preventing Strokes And MIs
Michael R. Jaff, DO
Ron Waksman, MD
Ido Weinberg, MD, MSc

3:28 – 3:33  Role Of Optimal Medical Treatment In Stroke Prevention: Does It Really Work
Michael R. Jaff, DO
Ido Weinberg, MD, MSc

3:34 – 3:39  DEBATE: The Truth About Statin Toxicity: Has It Been Overplayed By The FDA And By The Media
Bruce A. Perler, MD, MBA

3:40 – 3:45  DEBATE: Statins May Be Harmful And Should Be Used Less
Sherif Sultan, MD

3:46 – 3:51  How Should We Interpret The JUPITER Trial Showing The Value Of Statins: Has JUPITER Gotten A Bum Rap
Michael R. Jaff, DO

3:52 – 3:57  Do L-Arginine Supplements Help Vascular Patients: When And How Should They Be Given
Vikram S. Kashyap, MD

3:58 – 4:03  Carotid Glomectomy Is A Good Treatment For Syncopal Vasosphegia: How To Do It
Erik E. Debing, MD, PhD

4:04 – 4:09  Interactive Telephone Program To Allow Daily Monitoring Of Vascular Patients
John (Jeb) W. Hallett, MD

4:10 – 4:15  Comparative Performance Of Rotorex And Angiojet For Clot Removal From Lower Extremity Arteries: Advantages And Limitations Of Each
Hermann Steinkamp, MD

4:16 – 4:21  A New Device To Treat Resistant Hypertension By Carotid Baroreceptor Stimulation: The BAROSTIM Trial
Fred A. Weaver, MD

4:22 – 4:29  Routine Use Of Ultrasound Guidance And Micropuncture Makes Endovascular Access Safer: How To Do It
Peter A. Schneider, MD

4:30 – 4:37  Panel Discussion
SESSION 49 (Grand Ballroom East, 3rd Floor)
NEW TECHNIQUES; NEW CONCEPTS
(5-MINUTE TALKS)
Moderators: Michael B. Silva, Jr., MD
John J. Ricotta, MD

4:38 – 4:43 Laparoscopic Treatment Of The Arcuate Ligament Syndrome: Technique, Indications And Results
Yves Alimi, MD

4:44 – 4:49 Is There Still A Place For Unilateral And Even Bilateral Hypogastric Embolization In 2012: How Safe Is It
Dieter Raithel, MD, PhD

4:50 – 4:55 Hypogastric Preservation In Patients With Common Iliac Aneurysms Using Off-The-Shelf Devices
Karthikeshwar Kasirajan, MD

4:56 – 5:01 Unusual Causes Of Upper Extremity Arterial Occlusive Disease
Kenneth J. Cherry, MD

5:02 – 5:07 Catheter Directed Prostaglandins Are An Effective Treatment For CLI: As The Sole Treatment Or As An Adjunct To Other Endovascular Therapy
Oscar L. Ojeda, MD
Marcelo Patero, MD

5:08 – 5:13 Carotid Interventions For Acute Stroke: When Are They Worthwhile And When Are They Not
R. Clement Darling III, MD

5:14 – 5:19 How Do Pericardial Patches Heal And Why Are They Likely to Resist Infection
Alan Dardik, MD, PhD

5:20 – 5:25 Imaging And Endovascular Techniques In The Removal Of Transvenous Pacer And ICD Leads
Ali Khoynezhad, MD, PhD

5:26 – 5:31 Update On Treatment Of Infected Abdominal And Thoracic Endografts: Is It A Solvable Or Hopeless Problem And Is Non-Excisional Treatment Ever Successful
Peter R. Taylor, MA, MChir

5:32 – 5:37 Non-Atherosclerotic Aortic Thrombosis: Causes, Diagnosis And Treatment
Cynthia K. Shortell, MD

5:38 – 5:43 The SoloPath Expandable Introducer Sheath: How Does It Work And How Can It Be Helpful In EVAR Procedures
Jeffrey P. Carpenter, MD

5:44 – 5:49 Management Of Infected CEA Patches: A 10-Year Experience
Ali F. AbuRahma, MD

5:50 – 5:55 In Situ Fenestration For Left Subclavian Revascularization During TEVAR Is Safer And Better Than Carotid Subclavian Bypass: How To Do It
Frank R. Arko, MD

5:56 – 6:01 Bell Bottom Iliac Limbs Have A Downside
Gustavo S. Oderich, MD

6:02 – 6:10 Panel Discussion
SESSION 50 (Grand Ballroom West, 3rd Floor)

UPDATES, NEW TECHNOLOGY, NEW CONCEPTS
(5-MINUTE TALKS)

Moderators: Herbert Dardik, MD
Dhiraj M. Shah, MD

3:10 – 3:15 Current Optimal Treatment Of Atrial Fibrillation In Vascular Patients
Jeffrey S. Berger, MD, MS

3:16 – 3:21 Prevalence Of Carotid Stenosis Varies According To Race: Highest In Caucasians And Native Americans
Caron B. Rockman, MD

James H. Black III, MD

3:28 – 3:33 Biodegradable Scaffolds (REMEDY Stent), DEBs And DESs, In The SFA: What Is Their Future
Sumaira Macdonald, MBChB, PhD

3:34 – 3:39 Can The Achilles Tendon Be Excised Safely And With Minimal Disability To Treat Bad Heel Wounds And Plantar Pedal Ulcers
Wayne Caputo, DPM
Clifford M. Sales, MD, MBA

3:40 – 3:45 Drug Eluting Balloon Evaluation For Lower Limb Multilevel Treatment – DEBELLUM Trial: 1-Year Results
Fabrizio Fanelli, MD
Plinio Rossi, MD

3:46 – 3:51 Bypasses For Hand Digital Ischemia: What Is Their Role And Their Results
R. Clement Darling III, MD

3:52 – 3:57 Retrohepatic Balloon Occlusion Of The IVC For Trauma And Renal Cell Cancer: How To Do It With Current Technology
Joseph S. Giglia, MD

3:58 – 4:03 Carotid-To-Axillary Bypass Is Useful As A Debranching Technique And Easier And Less Risky Than Carotid-To-Subclavian Bypass
Frank J. Criado, MD

4:04 – 4:09 VIATORR Covered Stent For Early TIPS And Its Effect On Hepatic Encephalopathy And Ascites: Other New Horizons In TIPS
Ziv J. Haskal, MD

4:10 – 4:15 Which Post EVAR Patients Need Minimal Follow-up Surveillance: What Should That Consist Of
Hence J.M. Verhagen, MD, PhD

4:16 – 4:21 Angioslide Angioplasty Balloon With Embolic Capture (Proteus Device): When To Use It And Evidence Of Effectiveness
Peter C.J. Goverde, MD

4:22 – 4:27 Outcomes Of Endovascular Treatment Of Lower Extremity Lesions Are Worse In Young Patients (<50)
Rabih A. Chaer, MD

4:28 – 4:34 Panel Discussion
SESSION 51 (Grand Ballroom West, 3rd Floor)
MORE NEW CONCEPTS, UPDATES AND NEW TECHNIQUES (5-MINUTE TALKS)

Moderators: Enrico Ascher, MD
Palma M. Shaw, MD

4:34 – 4:39
Limitations Of A Large Palmaz Stent For Treating Type I Endoleaks
Tilo Koelbel, MD, PhD

4:40 – 4:45
Recent Volumetric Analyses Of Post EVAR AAA Sac Behavior: Is Sac Enlargement Still A Concern
Mark F. Fillinger, MD

4:46 – 4:51
2-Stage Treatment For Aorto-Enteric Fistulas Following Aortic Reconstruction: A New Better Way
Gioacchino Coppi, MD

4:52 – 4:57
Siena Score For Evaluating AAAs Suitability For EVAR: What Is It And How Does It Help
Francesco Setacci, MD

4:58 – 5:03
Advantages And Early Results Of The ALTURA Ultra Low Profile AAA Endograft
Albrecht H. Kraimer, MD

5:04 – 5:09
Fascial Suture To Close Large Percutaneous Sheath Insertion Sites Cheaply And Effectively (The Larzon Technique): Tips And Tricks
Timothy A. Resch, MD, PhD

5:10 – 5:15
Cost Per Day Of Patency In Endo vs. Open Lower Extremity Revascularization Procedures
Manish Mehta, MD, MPH

5:16 – 5:21
Current Status Of Silver Impregnated Grafts To Treat Aortic Infection: Are We In The US Being Denied A Valuable Treatment Adjunct
Max Zegelman, MD, PhD

5:22 – 5:27
Antibiotic Drug Delivery Implants Facilitates Treatment Of Some Infected Vascular Prosthetic Grafts
Dennis F. Bandyk, MD

5:28 – 5:33
DW-MRI Based Evidence That Interruption Of Flow Embolic Protection With The MoMa Device Is Effective During CAS (The DESERVE Trial)
Giancarlo Biamino, MD, PhD

5:34 – 5:39
Optimal Current Use Of Anticoagulants And Antiplatelet Drugs In Patients Undergoing CEA
Timothy M. Sullivan, MD

5:40 – 5:45
Causes And Implications Of 30-Day Readmissions After AAA Repair: Endo And Open
K. Craig Kent, MD

5:46 – 5:51
BASIL Survival Prediction Model In Patients With CLI: Validation And Comparison With PREVENT And FINNUVASC Scores
Robert J. Hinchcliffe, MD

5:52 – 5:57
Importance Of Pressure Gradients In Assessing Hemodynamic Significant Vascular Lesions: A Simple Method To Measure Them
Ali Amin, MD, RVT

5:58 – 6:05
Panel Discussion
NEW DEVELOPMENTS AND UPDATES: EARLY CAROTID TREATMENT, TAKAYASU’S DISEASE AND TECHNIQUES FOR EVALUATING CAROTID PLAQUES NONINVASIVELY (5-MINUTE TALKS)

**Moderators:** Frans L. Moll, MD, PhD
Lucien D. Castellani, MD

6:40 – 6:45
Techniques For Crossing Over Difficult Aortic Bifurcations To Deliver Contralateral Interventions
Scott L. Stevens, MD

6:46 – 6:51
Outcomes Of Urgent CEA In Symptomatic Patients: Are They Acceptable
Gabriel Szendro, MD

6:52 – 6:57
Can The 14-Day Treatment Target For Symptomatic Carotid Disease Patients Be Met: Are The Outcomes Acceptable
A. Ross Naylor, MD

6:58 – 7:03
Results Of Urgent CEA In Symptomatic Patients: Can CAS Results Equal Them
Laura Capoccia, MD, PhD

7:04 – 7:09
Is Early Intervention For Symptomatic Carotid Stenosis As Good For CAS As CEA
Sumaira Macdonald, MBChB, PhD

7:10 – 7:15
How To Treat Cerebral Ischemia From Takayasu’s Disease
Zhong Gao Wang, MD

7:16 – 7:21
When Is Endovascular Treatment Of Takayasu’s With PTA, Stent Or Stent-Graft Indicated And Justified By The Results
Xiaoyun Luo, MD

7:22 – 7:27
Pros And Cons Of Open Bypass Surgery And Endovascular Procedures With Supra-aortic Lesions Due To Takayasu’s Disease
Young Wook Kim, MD

7:28 – 7:33
Panel Discussion
**Moderators:** Thomas S. Riles, MD
Allan L. Brook, MD

7:34 – 7:39
DEBATE: Key Findings In The SAMMPRIS Trial Showing Intracranial Stents To Be Less Effective Than Best Medical Treatment In Preventing Strokes
Colin P. Derdeyn, MD

7:40 – 7:45
DEBATE: SAMMPRIS Had Major Flaws And Reached Misleading Conclusions
L. Nelson Hopkins, MD

7:46 – 7:51
How To Make Endovascular Treatment Of Acute Strokes Work Best In 2012: Why Have Some Of The Trials To Date Been Negative
Don Frei, MD

7:52 – 7:57
Relationship Between IVUS-Characterized Plaque Morphology And Embolic Potential – Spontaneously And During CAS
Wei Zhou, MD
7:58 – 8:03 Dynamic Contrast Ultrasonography To Stratify Risk In Asymptomatic Carotid Stenosis Patients: How Does It Work
Alan H. Davies, MA, DM

8:04 – 8:09 3-D Ultrasound And MRI Assessment Of Carotid Plaques: Do Statins Result In Plaque Shrinkage And Other Beneficial Changes
Henrik Sillesen, MD, DMSc

8:10 – 8:15 How To Identify Asymptomatic Carotid Stenoses At High Risk For Causing A Stroke: Searching For The Holy Grail
Jose Fernandes e Fernandes, MD, PhD

8:16 – 8:21 Impact Of Contralateral Carotid Occlusion (CCO) On The Comparative Results Of CEA And CAS For Treatment Of Carotid Stenosis: CAS Is Equivalent To CEA With CCO
Joseph J. Ricotta II, MD, MS
Gilbert R. Upchurch, MD
Gregg S. Landis, MD

8:22 – 8:28 Panel Discussion

SESSION 53 (Grand Ballroom East, 3rd Floor)
MORE ABOUT THORACIC AND ABDOMINAL ANEURYSMS: MANAGEMENT OF COMPLICATIONS (5-MINUTE TALKS)
Moderators: K. Wayne Johnston, MD
Larry H. Hollier, MD

8:28 – 8:33 Current Treatment Of Para-Anastomotic Aneurysms After Open Surgery: They Are Easily Fixed Endovascularly
Arno von Ristow, MD

8:34 – 8:39 Endovascular Treatment Of Late Complications From Open AAA Surgery
Giancarlo Mansueto, MD

8:40 – 8:45 MRI Is Better Than CTA For Finding Endoleaks And Identifying Their Type: Why
Frans L. Moll, MD, PhD

8:46 – 8:51 EVAR Of Primary Infected (Mycotic) AAAs: Results Are Surprisingly Good But Not Universally So
Anders Wanhainen, MD, PhD
Martin Björck, MD, PhD

8:52 – 8:57 Techniques For Safe Open Conversion After Failed EVAR And TEVAR
Germano Melissano, MD
Roberto Chiesa, MD

8:58 – 9:03 Complications Of TEVAR For Treatment Of Traumatic Aortic Injury And How They Can Be Prevented And Treated
Ali Azizzadeh, MD

9:04 – 9:09 How To Treat AAAs With <14 mm Distal Necks Safely With Bifurcated Endografts
Gustavo S. Oderich, MD

9:10 – 9:15 Cost Effectiveness Of EVAR And Open Repair In The OVER Trial After 2 Years
Frank A. Lederle, MD

9:16 – 9:21 Thoracic Aortic Aneurysm In Patients With AAAs: How Common Are They And When Should They Be Looked For With Chest CT
Rabih A. Chaer, MD
Michel S. Makaroun, MD
SESSION 54 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN CAROTID DISEASE TREATMENT AND ASSOCIATED ISSUES
(5-MINUTE TALKS)
Moderators: Hans-Henning Eckstein, MD, PhD
John B. Chang, MD

10:00 – 10:05
A Postop MI With Only A Rise In Troponin Is A Bad Thing But No Worse A Predictor Of Late Mortality Than Any Stroke: Based On CREST And Other Data
Wesley S. Moore, MD

10:06 – 10:11
When Do Clot Retrieval Devices Work In Acute Stroke: Which Device Is Best – Merci, Penumbra, Solitaire: The SWIFT Trial
L. Nelson Hopkins, MD

10:12 – 10:17
CAS Or CEA For Carotid Disease Associated With Neck Radiation: Which Treatment Is Best
Frans L. Moll, MD, PhD

10:18 – 10:23
Value And Limitation Of Optical Coherence Tomography To Evaluate Carotid Plaques And Luminal Anatomy Before And After CAS
Carlo Setacci, MD

10:24 – 10:29
Simplified Safe Technique For Carotid Subclavian Bypass
Ramon Berguer, MD, PhD
Mark D. Morasch, MD

10:30 – 10:35
DEBATE: When Should A Shunt Be Used During CEA: From The VSGNE
Philip P. Goodney, MD, MS
Jack L. Cronenwett, MD

10:36 – 10:41
DEBATE: A Shunt Should Never Be Used During CEA: What Is Required To Use The No-Shunt Technique Safely
Russell H. Samson, MD, RVT

10:42 – 10:47
Panel Discussion
Moderators: Daniel G. Clair, MD
Thomas S. Riles, MD

10:48 – 10:53
Technical Tricks And Devices Make CAS Easier And Safer With The MoMa Flow Cessation Device And The 2 Wire PITON Catheter
Gioacchino Coppi, MD
SESSIONS 54–55

SESSION 55 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS AND CONTROVERSIAL ISSUES RELATED TO CAS AND CEA
(5-MINUTE TALKS)

Moderators: Peter A. Schneider, MD
Frank J. Veith, MD

11:42 – 11:47
Comparison Of 5 Different Guidelines For Treating Carotid Stenosis: How Can Such Differing Interpretations Be Drawn From The Same Data
Kosmas I. Paraskevas, MD
Dimitri P. Mikhailidis, MD
Frank J. Veith, MD

11:48 – 11:53
CREST Cost Comparisons Between CAS And CEA: Possible Flaws In The CREST Cost Data That Make Its Conclusions Misleading
W. Charles Sternbergh III, MD

11:54 – 11:59
Impact Of Cranial Nerve Defects (CRI) In CREST At One Year: These CRIs Were Minor And Not Equivalent To Strokes
Thomas G. Brott, MD

12:00 – 12:05
DEBATE: CEA vs. CAS In Symptomatic Patients: The Heart Should Not Rule The Head When Deciding Treatment Strategies
A. Ross Naylor, MD

12:06 – 12:11
DEBATE: CEA vs. CAS In Symptomatic Patients: The Heart Should Rule The Head When Deciding Treatment Strategies
Peter A. Schneider, MD
Which Carotid Patients Needing Invasive Treatment Do I Currently Send For CEA
Klaus D. Mathias, MD

Are CAS vs. CEA Trials Inherently Biased: Critical Appraisal Of Endpoints
Timothy M. Sullivan, MD

DEBATE: Many Selected Asymptomatic Carotid Stenosis Patients Benefit From CEA: How Should They Be Picked
Bruce A. Perler, MD, MBA

DEBATE: Not So: With Asymptomatic Carotid Stenosis Patients Any Benefit Of Invasive Treatment Is Outweighed By The Risks
Anne L. Abbott, MD, PhD

Predictors Of Early Adverse Outcomes After CEA: Are They An Indication For CAS
Erik E. Debing, MD, PhD

Current Strategies For Treating Carotid And Vertebral Dissections
L. Nelson Hopkins, MD

Is A Postop MI With Only A Rise In Troponin A Bad Thing And Predictive Of Late Increased Mortality Risk
Andres Schanzer, MD

Current Stent Design For CAS Procedures Is Inadequate: What Is On The Horizon To Remedy This
Sumaira Macdonald, MBChB, PhD

ENDO May 2023

SESSION 56 (Grand Ballroom East, 3rd Floor)

NEW HORIZONS, NEW CONCEPTS AND LATE BREAKING DEVELOPMENTS (5-MINUTE TALKS)

Moderators: John E. Connolly, MD
Enrico Ascher, MD

Endovascular Conversion Of Open Surgical Failures And Complications: Tips And Tricks
Jos C. van den Berg, MD, PhD

Technique Of Balloon Common Iliac Occlusion To Facilitate Antegrade Wire Passage Through Flush Iliac Occlusions: A Cheaper Safer Way
Peter H. Lin, MD

Proportion Of CLI Patients Requiring Open Surgery When Endo Is The First And Favored Option: A Totally Endo First Strategy May Not Be Cost Effective
Firas F. Mussa, MD

What Happens When SFA And Popliteal Stents Fail
Vincent L. Rowe, MD
Steven G. Katz, MD

CFA Stenting Can Be Done Safely And Effectively In An Outpatient Setting: Tips And Tricks
Sam S. Ahn, MD, MBA

Results Of The DUET Trial: A RCT Comparing Ultrasound Enhanced vs. Standard Thrombolysis For Arterial Occlusions
Jean-Paul de Vries, MD, PhD

Xenograft Pericardial Tubes And Radical Debridement Of Surrounding Tissues: A New Concept For Treating Prosthetic Graft Infections
Jürg Schmidli, MD
SESSIONS 56–57

SUNDAY

2:02 – 2:07
Current Optimal Treatment Of Carotid And Vertebral Spontaneous And Traumatic Dissections
Irwin V. Mohan, MD

2:08 – 2:13
Update On The SETA Balloon Expandable AAA Endograft: Mid-Term Clinical Experience
Hernan G. Bertoni, MD

2:14 – 2:18
Panel Discussion

2:20 – 2:25
Open Aortic Repair After Failed EVAR: Tips And Tricks To Lower Morbidity And Mortality
R. Clement Darling III, MD

Moderators: James F. McKinsey, MD Lucien D. Castellani, MD

2:26 – 2:31
Crossing Lower Extremity CTOs Using The VIANCE And ENTEER Devices: Final Results Of The PFAST Trial
Subhash Banerjee, MD

2:32 – 2:37
Endovascular Techniques For Carotid And Cerebral Artery Thrombectomy For Acute Stroke: Experience In >130 Patients
Klaus D. Mathias, MD

2:38 – 2:43
Interventions Performed Within 1 Week Of A Neurological Event: Outcomes Of CAS Are Better Than CAS (Data From The EVA-3S, The SPACE And The ICSS Trials)
Gustav Fraedrich, MD
Barbara Rantner, MD
Georg Goebel, MD and Leo H. Bonatti, MD
On behalf of the CSTC

2:44 – 2:49
How Was CREST Data Presented In The FDA Application For Low Risk Carotid Stenting In A Way That Renders Them Misleading
Thomas G. Brott, MD

2:50 – 2:55
Filters vs. Flow Reversal And Occlusion: Advantages And Disadvantages Of Both
Claudio J. Schonholz, MD

2:56 – 3:01
SVS Registry Results Show CEA To Have Superior Outcomes To Those Of CAS In Symptomatic And Asymptomatic Patients Over 65
Brian G. Rubin, MD

3:02 – 3:07
Can Medical Treatments Decrease AAA Growth Rates: Prospects For The Future
Russell H. Samson, MD, RVT

3:08 – 3:14
Panel Discussion

3:15 – 3:20
Comparative Outcomes Of Bell Bottom Technique And Hypogastric Exclusion For Common Iliac Aneurysms Treated By EVAR: Bell Bottom Wins
Mark K. Eskandari, MD

SESSION 57 (Grand Ballroom East, 3rd Floor)
LATE BREAKING TOPICS OF PARTICULAR INTEREST (5-MINUTE TALKS)

Moderators: Kenneth Ouriel, MD, MBA Frank J. Veith, MD

3:21 – 3:26
4-Year Results With Sandwich Technique For Treating Common And Internal Iliac Aneurysms
Armando C. Lobato, MD, PhD

3:27 – 3:32
Iliac Branched Devices Work Well In Worldwide Experience: The PRESERVE Trial
W. Anthony Lee, MD
Infected AAAs: Endovascular Therapy Should Be The First Choice: How To Make It Work With 2-6 Years Follow-up
Boonpratit Kritpracha, MD

Novel Technique For Treating Type II Endoleaks By Accessing AAA Sac And Nidus Via Distal Endograft Attachment Site
Giochino Coppi, MD

Flow Control To Prevent Embolic Complications During Endovascular Treatment Of Aortoiliac Occlusive Disease
Claudio I. Schonholz, MD

Treatment Of Refractory Postthrombotic Syndrome By Cutting Balloon Angioplasty Of The Popliteal Vein
Thomas O. McNamara, MD

Military Translational Research To Develop A New Fluoroscopy-Free Endovascular Balloon Occlusion System To Treat End-Stage Shock
Todd E. Rasmussen, MD

Double Chimney Technique To Treat Arch Aneurysms: How To Make Them Work
Jan S. Brunkwall, MD, PhD

Endovascular Graft Treatment Of Popliteal Aneurysms Is As Effective As Open Surgery In Terms Of Long-Term Patency
Michel S. Makaroun, MD
Rabih A. Chaer, MD

Panel Discussion

Raffle Drawing – You Must Be Present To Win

Symposium Ends

Save The Date: November 20-24, 2013
Hilton New York
Faculty

Anne L. Abbott, MD, PhD, FRACP, FR ACP
Melbourne, Australia

Dorothy B. Abel, BSBE
Silver Spring, Maryland

Apolonia E. Abramowicz, MD
Bronx, New York

Kenneth D. Abreo, MD
Shreveport, Louisiana

Ali F. AbuRahma, MD
Charleston, West Virginia

Giancarlo G.C. Accarino, MD
Salerno, Italy

Charles W. Acher, MD
Madison, Wisconsin

Mark A. Adelman, MD
New York, New York

Sam S. Ahn, MD, MBA, FACS
Los Angeles, California and Dallas, Texas

Afsaneh Alavi, MD, FRCPC
Toronto, Ontario, Canada

Yves Alimi, MD
Marseille, France

Jose I. Almeida, MD, RVT, FACS
Miami, Florida

Ali Amin, MD, RVT, FACS, FACC
Reading, Pennsylvania

Max Amor, MD
Essey-Lès-Nancy, France

Gary M. Ansel, MD
Columbus, Ohio

Frank R. Arko, MD
Charlotte, North Carolina

John E. Aruny, MD
New Haven, Connecticut

Enrico Ascher, MD
Brooklyn, New York

Afshin Assadian, MD
Vienna, Austria

Ali Azizzadeh, MD
Houston, Texas

Nobuyoshi Azuma, MD
Asahikawa, Hokkaido, Japan

Martin R. Back, MD
Tampa, Florida

Jörn O. Balzer, MD, PhD
Mainz, Germany

Dennis F. Bandyk, MD
La Jolla, California

Subhash Banerjee, MD
Dallas, Texas

Richard A. Baum, MD, MPA, MBA
Boston, Massachusetts

Jonathan D. Beard, MD
Sheffield, United Kingdom

Jean-Pierre Becquemin, MD, FRCS
Crestil, France

Michael Belkin, MD
Boston, Massachusetts

Amira Benjelloun, MD
Rabat, Morocco

Jeffrey S. Berger, MD, MS, FAHA, FACC
New York, New York

Patrice F. Bergeron, MD
Marseille, France

Ramon Berguer, MD, PhD
Ann Arbor, Michigan

Todd Berland, MD
New York, New York

Hernan G. Bertoni, MD
Buenos Aires, Argentina

Giancarlo Biamino, MD, PhD
Mergocchio (AV), Italy

Giorgio M. Biasi, MD
Milan, Italy

Jean Bismuth, MD
Houston, Texas

James H. Black III, MD
Baltimore, Maryland

Jan D. Blankensteijn, MD
Amsterdam, The Netherlands

John Blebea, MD, MBA
Tulsa, Oklahoma

Dittmar Boeckler, MD
Heidelberg, Germany

Thomas Boeni, MD
Zurich, Switzerland

Amman Bolia, MD
Leicester, United Kingdom

Marc Bosiers, MD
Dendermonde, Belgium

Bruce J. Brenner, MD
Livingston and Newark, New Jersey

Marc A. Brenner, DPM
Glendale and Manhasset, New York

Fleur E. Brolmann, MD
Amsterdam, The Netherlands

Allan L. Brooker, MD
Brons, New York

Thomas G. Brott, MD
Jacksonville, Florida

O. William Brown, MD, JD
Royal Oak, Michigan

Elchanan Bruckheimer, MBBS
Petah-Tikva, Israel

Jan S. Brunkwall, MD, PhD
Cologne, Germany

Clifford J. Buckley, MD
Temple, Texas

Nick J. Burrill, BSc, MB, BChir, MRCS, FRCR
London, United Kingdom

Ronald G. Bush, MD
Dayton, Ohio

Jacques Busquet, MD
Paris, France

Keith D. Calligaro, MD
Philadelphia, Pennsylvania

Richard P. Cambria, MD
Boston, Massachusetts

Piergiorgio Cao, MD, FRCS
Rome, Italy

Lou Caplan, MD
Boston, Massachusetts

Laura Capoccia, MD, PhD
Rome, Italy

Wayne Caputo, DPM
Bellevue, New Jersey and New York, New York

Jeffrey P. Carpenter, MD
Carmen, New Jersey

Lucien D. Castellani, MD
Tours, France
Sumaira Macdonald, MBChB (Comm), FRCP, FRCR, PhD
Newcastle-upon-Tyne, United Kingdom
Edward G. Mackay, MD
St. Petersburg, Florida
Michel S. Makaroun, MD
Pittsburgh, Pennsylvania
Thomas S. Maldonado, MD
New York, New York
Martin Malina, MD, PhD
Malmö, Sweden
Nicola Mangialardi, MD
Rome, Italy
Giancarlo Mansueto, MD
Verona, Italy
Marco G. Manzi, MD
Vicenza, Italy
Michael L. Marin, MD
New York, New York
William A. Marston, MD
Chapel Hill, North Carolina
Tara M. Mastracci, MD
Cleveland, Ohio
Elna M. Masuda, MD
Honolulu, Hawaii
Klaus D. Mathias, MD
Dortmund, Germany
Jon S. Matsumura, MD
Madison, Wisconsin
Jerry Matteo, MD
Jacksonville, Florida
James May, MD, MS, FRACS, FACS
Sydney, Australia
Dieter O. Mayer, MD
Zurich, Switzerland
James F. McKinsey, MD
New York, New York
Robert B. McLafferty, MD
Springfield, Illinois
Thomas O. McNamara, MD
Los Angeles, California
Manish Mehta, MD, MPH
Albany, New York
George H. Meier III, MD
Cincinnati, Ohio
Mark H. Meissner, MD
Seattle, Washington
Germano Melissano, MD
Milan, Italy
Philip M. Meyers, MD
New York, New York
Claude Mialhe, MD
Monaco
Joseph L. Mills, MD
Tucson, Arizona
Ross Milner, MD
Maywood, Illinois
Erich Minar, MD
Vienna, Austria
David J. Minion, MD
Lexington, Kentucky
J. Mocco, MD, MS
Nashville, Tennessee
Irwin V. Mohan, MD, FRCS, FEBVS, FRACS
Sydney, Australia
Louise Moise, MD, MSc
London, Canada
Frans L. Moll, MD, PhD
Utrecht, The Netherlands
Gregory L. Moneta, MD
Portland, Oregon
Samuel R. Money, MD, MBA
Scottsdale, Arizona
Wesley S. Moore, MD
Los Angeles, California
Robert A. Morgan, MD
London, United Kingdom
Nicholas J. Morrissey, MD
New York, New York
Alber Y. Mousa, MD
Charleston, West Virginia
Patrick E. Muck, MD, FACS
Cincinnati, Ohio
Bart E. Muhs, MD, PhD
New Haven, Connecticut
Firas F. Mussa, MD
New York, New York
Jihad A. Mustapha, MD
Wyoming, Michigan
Pramook Mutirangura, FRCS (Edinburgh)
Bangkok, Thailand
Gregory J. Nadolski, MD
Philadelphia, Pennsylvania
A. Ross Naylor, MD, FRCS
Leicester, United Kingdom
Peter K. Nelson, MD
New York, New York
Richard F. Neville, MD
Washington, District of Columbia
Andrew N. Nicolaides, MS, FRCS
Nicosia, Cyprus
Christoph A. Nienaber, MD, PhD
Rostock, Germany
Furuzan Numan, MD
Istanbul, Turkey
Thomas F. O'Donnell, Jr., MD
Boston, Massachusetts
Gustavo S. Oderich, MD, FACS
Rochester, Minnesota
Oscar L. Ojeda, MD
Buenos Aires, Argentina
Karl H. Orend, MD
Ulm, Germany
Kenneth Ouriel, MD, MBA, FACS, FACC
New York, New York
Peter J. Pappas, MD
Brooklyn, New York
Kosmas I. Paraskevas, MD
Athens, Greece
Juan C. Parodi, MD
Buenos Aires, Argentina
Aman B. Patel, MD
New York, New York
William D. Paulson, MD
Augusta, Georgia
Dusan Pavcnik, MD, PhD
Portland, Oregon
Eric K. Peden, MD
Houston, Texas
Patrick Peeters, MD
Bonheiden, Belgium
Hair Batipsky, MD, FACS
Baltimore, Maryland

Ivo Petrov, MD, PhD
Sofia, Bulgaria

Timothy A. Pfleiderer, MD
Peoria, Illinois

Paul Pittaluga, MD
Nice, France

Don Poldermans, MD
Spijkense, The Netherlands

Janet T. Powell, MD, PhD
London, United Kingdom

Richard J. Powell, MD
Lebanon, New Hampshire

Joseph D. Raffetto, MD
West Roxbury, Massachusetts

Dieter Raithel, MD, PhD
Nuremberg, Germany

Dheeraj Rajan, MD, FRCPC
Toronto, Canada

Seshadri Raju, MD
Pflowood, Mississippi

Zoran Rancic, MD, PhD
Zurich, Switzerland

Hisham Rashid, MSc, FRCS, FRCSI(Gen)
London, United Kingdom

Peter A. Rasmussen, MD
Cleveland, Ohio

Todd E. Rasmussen, MD, FACS
Fort Sam Houston (San Antonio), Texas

Allan W. Reid, FRCR
Glasgow, United Kingdom

Donald B. Reid, MD
Wishaw, Scotland

Michel M.P. Reijn, MD, PhD
Arnhem, The Netherlands

Timothy A. Resch, MD, PhD
Malmo, Sweden

Vicente Riambau, MD, PhD
Barcelona, Spain

Jean-Baptiste Ricco, MD, PhD
Poitiers, France

Norman M. Rich, MD, FACS, DMCC
Bethesda, Maryland

Götz M. Richter, MD, PhD
Stuttgart, Germany

John J. Ricotta, MD
Washington, District of Columbia

Joseph J. Ricotta II, MD, MS
Atlanta, Georgia

Thomas S. Riles, MD
New York, New York

Krishna J. Rocha-Singh, MD
Springfield, Illinois

Caron B. Rockman, MD
New York, New York

Sean P. Roddy, MD
Albany, New York

Julio A. Rodriguez-Lopez, MD
Phoenix, Arizona

Marco Romaneli, MD, PhD
Pisa, Italy

Sonia Ronchey, MD
Rome, Italy

Eric E. Roselli, MD
Cleveland, Ohio

Kenneth Rosenfeld, MD
Boston, Massachusetts

David Rosenthal, MD
Atlanta, Georgia

Plinio Rossi, MD
Rome, Italy

Vincent L. Rowe, MD
Los Angeles, California

Howard A. Rowley, MD
Monroe, Wisconsin

Prabir Roy-Chaudhury, MD, PhD
Cincinnati, Ohio

Brian G. Rubin, MD
St. Louis, Missouri

Steven H. Rudolph, MD
Brooklyn, New York

Maria Antonella Ruffino, MD
Torino, Italy

Theodore F. Saad, MD
Newark, Delaware

Nirvana Sadaghianlou, MD
Nice, France

Mikel Sadek, MD
New York, New York

Hazin J. Safi, MD
Houston, Texas

Clifford M. Sales, MD, MBA
Summit, New Jersey

Russell H. Samson, MD, RVT, FACS
Sarasota, Florida

Luis A. Sanchez, MD
St. Louis, Missouri

Wilhelm Sandmann, MD
Kamp-Lintfort, Germany

Timur P. Sarac, MD
Cleveland, Ohio

Richard R. Saxon, MD
San Diego, California

Pamela W. Schafer, MD
Boston, Massachusetts

Andres Schanzer, MD
Worcester, Massachusetts

Dierk Scheinert, MD
Leipzig, Germany

Larry A. Scher, MD
Bronx, New York

Marc L. Schermerhorn, MD
Boston, Massachusetts

A. Frederick Schild, MD
Phoenix, Arizona

Jürg Schmidli, MD
Bern, Switzerland

Andrej Schmidt, MD
Leipzig, Germany

Darren B. Schneider, MD
New York, New York

Peter A. Schneider, MD
Honolulu, Hawaii

Claudio J. Schonholz, MD
Charleston, South Carolina

Geert Willem H. Schurink, MD, PhD
Maastricht, The Netherlands

Lewis B. Schwartz, MD
Abbott Park, Illinois

Francesco Serino, MD
Rome, Italy

Carlo Setacci, MD
Siena, Italy

Francesco Setacci, MD
Siena, Italy
<table>
<thead>
<tr>
<th>Name</th>
<th>City, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Settle, MD</td>
<td>Austin, Texas</td>
</tr>
<tr>
<td>Dhiraj M. Shah, MD</td>
<td>Albany, New York</td>
</tr>
<tr>
<td>Joseph N. Shams, MD</td>
<td>New York, New York</td>
</tr>
<tr>
<td>Nick Shaper, FRCS</td>
<td>Bradford, England</td>
</tr>
<tr>
<td>Palma M. Shaw, MD</td>
<td>Durham, North Carolina</td>
</tr>
<tr>
<td>Cynthia K. Shortell, MD</td>
<td>Boston, Massachusetts</td>
</tr>
<tr>
<td>Chang Shu, MD</td>
<td>Chang Sha, Hunan Province, China</td>
</tr>
<tr>
<td>R. Gary Sibbald, MD</td>
<td>Toronto, Canada</td>
</tr>
<tr>
<td>Anton N. Sidawy, MD</td>
<td>Washington, District of Columbia</td>
</tr>
<tr>
<td>Henrik Sillesen, MD, DMSc</td>
<td>Copenhagen, Denmark</td>
</tr>
<tr>
<td>Michael B. Silva, Jr., MD</td>
<td>Galveston, Texas</td>
</tr>
<tr>
<td>Tony P. Smith, MD</td>
<td>Durham, North Carolina</td>
</tr>
<tr>
<td>Björn Sonesson, MD, PhD</td>
<td>Malmö, Sweden</td>
</tr>
<tr>
<td>Thomas A. Sos, MD</td>
<td>New York, New York</td>
</tr>
<tr>
<td>Francesco Spinelli, MD</td>
<td>Messina, Italy</td>
</tr>
<tr>
<td>James C. Stanley, MD</td>
<td>Ann Arbor, Michigan</td>
</tr>
<tr>
<td>Benjamin W. Starnes, MD</td>
<td>Seattle, Washington</td>
</tr>
<tr>
<td>Barry Stein, MD, FSIR, FACR</td>
<td>Hartford, Connecticut</td>
</tr>
<tr>
<td>Hermann Steinkamp, MD</td>
<td>Berlin, Germany</td>
</tr>
<tr>
<td>W. Charles Sterneberg III, MD</td>
<td>New Orleans, Louisiana</td>
</tr>
<tr>
<td>Scott L. Stevens, MD</td>
<td>Knoxville, Tennessee</td>
</tr>
<tr>
<td>Gregg W. Stone, MD</td>
<td>New York, New York</td>
</tr>
<tr>
<td>Michael C. Stoner, MD</td>
<td>Greenville, North Carolina</td>
</tr>
<tr>
<td>Timothy M. Sullivan, MD</td>
<td>Minneapolis, Minnesota</td>
</tr>
<tr>
<td>Sheriff Sultan, MD, FRCS, EBQS-VASC</td>
<td>Galway, Ireland</td>
</tr>
<tr>
<td>Bauer E. Sumpio, MD, PhD</td>
<td>New Haven, Connecticut</td>
</tr>
<tr>
<td>Jesper Swendsborg, MD, PhD</td>
<td>Stockholm, Sweden</td>
</tr>
<tr>
<td>Gabriel Szendro, MD</td>
<td>Beer Sheva, Israel</td>
</tr>
<tr>
<td>Victor E. Tapson, MD</td>
<td>Durham, North Carolina</td>
</tr>
<tr>
<td>Apostolos K. Tassiopoulos, MD</td>
<td>Stony Brook, New York</td>
</tr>
<tr>
<td>Peter R. Taylor, MA, MChir, FRCS, ARCM</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>Robert W. Thompson, MD</td>
<td>St. Louis, Missouri</td>
</tr>
<tr>
<td>Carlos H. Timaran, MD</td>
<td>Dallas, Texas</td>
</tr>
<tr>
<td>Giovanni Torsello, MD</td>
<td>Münster, Germany</td>
</tr>
<tr>
<td>Magdél Trinidad-Vazquez, MD</td>
<td>Guadalajara Jalisco, Mexico</td>
</tr>
<tr>
<td>Ramesh K. Tripathi, MD, FRCS</td>
<td>Bangalore, India</td>
</tr>
<tr>
<td>Claude D. Vaissic, MD</td>
<td>Le Chesnay, France</td>
</tr>
<tr>
<td>S. Rao Vallabhaneni, MD, FRCS</td>
<td>Liverpool, United Kingdom</td>
</tr>
<tr>
<td>Jos C. van den Berg, MD, PhD</td>
<td>Lugano, Switzerland</td>
</tr>
<tr>
<td>Renate R. van den Bos, MD, PhD</td>
<td>Rotterdam, The Netherlands</td>
</tr>
<tr>
<td>Isabelle Van Herzeel, MD, MD</td>
<td>Ghent, Belgium</td>
</tr>
<tr>
<td>Marc R.H.M. van Sambeek, MD, PhD</td>
<td>Eindhoven, The Netherlands</td>
</tr>
<tr>
<td>Michael A. Vasquez, MD, RVT</td>
<td>Buffalo, New York</td>
</tr>
<tr>
<td>Joseph A. Vassalotti, MD</td>
<td>New York, New York</td>
</tr>
<tr>
<td>Frank J. Veith, MD</td>
<td>Cleveland, Ohio and New York, New York</td>
</tr>
<tr>
<td>Hence J.M. Verhagen, MD, PhD</td>
<td>Rotterdam, The Netherlands</td>
</tr>
<tr>
<td>Eric L.G. Verhoeven, MD, PhD</td>
<td>Nürnberg, Germany</td>
</tr>
<tr>
<td>Hester Vermeulen, PhD</td>
<td>Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>Thomas M. Vesely, MD</td>
<td>St. Louis, Missouri</td>
</tr>
<tr>
<td>J. Leonel Villavicencio, MD</td>
<td>Bethesda, Maryland, and Washington, District of Columbia</td>
</tr>
<tr>
<td>Arnon Ron bio, MD</td>
<td>Rio de Janeiro, Brazil</td>
</tr>
<tr>
<td>Thomas W. Wakefield, MD</td>
<td>Ann Arbor, Michigan</td>
</tr>
<tr>
<td>Ron Waksman, MD</td>
<td>Washington, District of Columbia</td>
</tr>
<tr>
<td>Craig M. Walker, MD</td>
<td>Houma, Louisiana</td>
</tr>
<tr>
<td>Jeffrey Y. Wang, MD</td>
<td>Rockville, Maryland</td>
</tr>
<tr>
<td>Zhong Gao Wang, MD</td>
<td>Beijing, China</td>
</tr>
<tr>
<td>Anders Wanhainen, MD, PhD</td>
<td>Uppsala, Sweden</td>
</tr>
<tr>
<td>Haimanot (Monnie) Vasse, MD, MPH, FASN</td>
<td>Atlanta, Georgia</td>
</tr>
<tr>
<td>Fred A. Weaver, MD</td>
<td>Los Angeles, California</td>
</tr>
<tr>
<td>Lawrence Wechsler, MD</td>
<td>Pittsburgh, Pennsylvania</td>
</tr>
<tr>
<td>Ido Weinberg, MD, MSc</td>
<td>Boston, Massachusetts</td>
</tr>
</tbody>
</table>
### Full Registration

<table>
<thead>
<tr>
<th>Category</th>
<th>Tuition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Practicing Physicians</td>
<td>$1395</td>
</tr>
<tr>
<td>Practicing Physicians Combination Rate</td>
<td>$1895</td>
</tr>
<tr>
<td>US and Canadian Vascular Surgery Fellows</td>
<td></td>
</tr>
<tr>
<td>In Training</td>
<td></td>
</tr>
<tr>
<td>Non-U.S. Fellows, Nurse Practitioners</td>
<td></td>
</tr>
<tr>
<td>Physician Assistants</td>
<td>$695</td>
</tr>
<tr>
<td>Residents, Technologists</td>
<td>$650</td>
</tr>
<tr>
<td>Allied Health Care Professionals</td>
<td>$950</td>
</tr>
<tr>
<td>US and Canadian Vascular Surgery Fellows</td>
<td></td>
</tr>
<tr>
<td>Residents, Physicians</td>
<td></td>
</tr>
<tr>
<td>Nurse Practitioners</td>
<td></td>
</tr>
<tr>
<td>Physician Assistants</td>
<td></td>
</tr>
<tr>
<td>Residents, Technologists</td>
<td></td>
</tr>
<tr>
<td>Allied Health Care Professionals</td>
<td></td>
</tr>
<tr>
<td>US and Canadian Vascular Surgery Fellows</td>
<td></td>
</tr>
<tr>
<td>Residents, Physicians</td>
<td></td>
</tr>
<tr>
<td>Nurse Practitioners</td>
<td></td>
</tr>
<tr>
<td>Physician Assistants</td>
<td></td>
</tr>
<tr>
<td>Residents, Technologists</td>
<td></td>
</tr>
<tr>
<td>Allied Health Care Professionals</td>
<td></td>
</tr>
</tbody>
</table>

*Tuition is provided through an Educational Grant by W.L. Gore & Associates, Inc.*

**Letter of verification from Chief of Service must be faxed to 888-418-7043.**

### Component Meetings

<table>
<thead>
<tr>
<th>Meeting</th>
<th>Tuition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday Only - Endovenous Management of Varicose Veins</td>
<td>$345</td>
</tr>
<tr>
<td>Wednesday Only - Hemodialysis Access</td>
<td>$345</td>
</tr>
<tr>
<td>Wednesday Only - WOUNDS</td>
<td>$345</td>
</tr>
<tr>
<td>Wednesday Only - WOUNDS (nurses only)</td>
<td>$145</td>
</tr>
<tr>
<td>Wednesday Only - Emerging Management Options for Pulmonary Embolism</td>
<td></td>
</tr>
<tr>
<td>Wednesday Only - Management of Proximal Venous Obstruction</td>
<td></td>
</tr>
</tbody>
</table>

*Included in all registration categories*

### Refund

There is a $95 cancellation fee if canceled by October 19, 2012. No refunds will be made thereafter.

### Online

http://www.VEITHsymposium.org

### Phone

800-987-9314, Ext. 200 or 718-549-3140 with your payment information.

### Fax

the reverse form with your credit card payment to 888-418-7043

### Mail

this form with your payment to:
The Cleveland Clinic Educational Foundation
Attn: VEITH 020892
P.O. Box 931653
Cleveland, OH 44193-1082

### Additional Information

VEITHsymposium
4455 Douglas Avenue, Suite 11E
Riverside, New York 10471

Phone: 800-987-9314 or 718-549-3140

E-mail: registrar@veithsymposium.org or admin@veithsymposium.org
Full Registration
☐ Practicing Physicians ............................................................... $1395
☐ Practicing Physicians Combination Rate
VEITHsymposium and AVIDsymposium ..................................... $1995
☐ US and Canadian Vascular Surgery Fellows
In Training* .................................................................Complimentary
☐ Non-U.S. Fellows ☐ Nurse Practitioners
☐ Physician Assistants ........................................................... $695
☐ Residents ☐ Nurses ☐ Technologists................................. $650
☐ Allied Health Care Professionals ........................................... $950
* Tuition is provided through an Educational Grant by W.L. Gore & Associates, Inc.
Letter of verification from Chief of Service must be faxed to 888-418-7043.

Component Meetings (Tuition includes access to any Wednesday Only meeting.)
☐ Wednesday Only - Endovenous Management of Varicose Veins ................................................................. $345
☐ Wednesday Only - Hemodialysis Access ................................................. $345
☐ Wednesday Only - WOUNDS ......................................................... $345
☐ Wednesday Only - WOUNDS (nurses only)................................. $145
☐ Wednesday Only - Emerging Management Options for Pulmonary Embolism ........... Included in all tuition categories
☐ Wednesday Only - Management of Proximal Venous Obstruction.............................. Included in all tuition categories

First Name: ___________________________________________________
Last Name (Surname): ____________________________________________
Degree: _______________________________________________________
Specialty: _____________________________________________________
☐ Physician ☐ Non-Physician Cleveland Clinic Employee? ☐ Yes ☐ No
Affiliation: _____________________________________________________
Address Type: ☐ Home ☐ Other
Address:
City: ____________________________ State/Province ____________________________
Zip Code: ________________________ Country ________________________________
E-mail: ___________________________________________________________
(Valid registrant's e-mail address is required for confirmation and CME certificate.)
Phone: __________________________ Fax: ____________________________

Payment Method
Check: Please make checks payable to the Cleveland Clinic Educational Foundation and mail to:
The Cleveland Clinic Educational Foundation
Attn: VEITH 020892
P.O. Box 931653
Cleveland, OH 44193-1082

Name on Card: ______________________________________________________
Credit Card Number: _________________________________________________
Verification Code: _____________ Expiration Date _______________________
(3-4 Digit Code on Credit Card)
Zip Code: ________________________ Country ______________________________
Signature: _________________________________________________________
SAVE THE DATE

Wednesday – Sunday, November 20–24, 2013

Symposium Chairman
Frank J. Veith, MD

Symposium Co-Chairmen
Enrico Ascher, MD
Kenneth Ouriel, MD, MBA
Daniel G. Clair, MD

Sponsored by

Cleveland Clinic

www.VEITHsymposium.org
WEDNESDAY, NOVEMBER 14, 2012

- Hemodialysis Access
- Emerging Management Options for Pulmonary Embolism
- Management of Proximal Venous Obstruction
- Endovenous Management of Varicose Veins
- WOUNDS
- Multidisciplinary Acute Stroke Management

AGAIN THIS YEAR
6th Annual Poster Session, Wednesday – Friday, November 14 – 16, 2012